下列情形中哪一項有相同的反應速率

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Actual Study Start Date : October 18, 2022
Estimated Primary Completion Date : July 15, 2024
Estimated Study Completion Date : August 15, 2025

1.Experimental: Lebrikizumab (Cohort 1)
Participants who are 6 years to <18 years of age, 12 years to <18 years of age who weigh <40 kilogram (kg) or 6 years to <12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).

Dosing will be based on weight.

Drug: Lebrikizumab
Administered SC
Other Names:
LY3650150
DRM06

Drug: Topical corticosteroid
Topical corticosteroid

2.Experimental: Lebrikizumab (Cohort 2)
Participants who are 6 months to <6 years of age, 2 years to <6 years of age or 6 months to <2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.

Dosing will be based on weight.

Drug: Lebrikizumab
Administered SC
Other Names:
LY3650150
DRM06

Drug: Topical corticosteroid
Topical corticosteroid

3.Placebo Comparator: Placebo
Participants will receive placebo matching lebrikizumab by SC injections with a TCS.


2021/����/29 �� ���X1��5�a�U�������Ҹ�p��,�p�W
ir.aslanpharma.com/static-files/a3f199f7-f90f-43e0-8068-18a04a09edc5

2021/02/24 �p��3.52����/��
ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14

2021/03/01 ���G1b�����ƾ�
ir.aslanpharma.com/static-files/73f9ba3a-6822-48e5-ba31-886e0617b68d

2021/03/02 �]�P4����/��
ir.aslanpharma.com/static-files/3e007d02-a765-4a15-83c3-47aa257d8f49

���p���멳�H�e,�w���Ѫ�1b�����ƾ�.

�̮ɵ{
�Ĥ@���p�ұN�b2023�~3��15��H�e�����B�_�h�������D
����G7*80%*92%=5.15����/��

�o�O2021/02�����Ҧ�
5x80%x92%=3.68....�p��
2021/03/3...4�����]销

�ӷ��ɤ��멳�}�l���D

�����q�b�|��줽�G2b�ƾڡB�å]销��ӶҥH��T������D

�Q���ʮɾ��b���~��!

��������T���{�ɤ~�|���n���Q���ʻ��ȡD
�H�W�ӤH�ݪk!

�j�x���ʡB³�����!

���q���ȴN�b15~25����/�Ѥ������|�j�D

�p�Q���ʻ�40������
20�U��ADR�ѥ�

�C�ѳ�20�����D

�n�����I
���|���F�C
�@�@�@�@
�M�H�e�@�ˡA�W�[�@���ꥻ�B�A
ADR�q10�U�d�ѼW��20�U�d�ѡC
�ثe�w�o���7�U�Ѥd��ADR
�]���q�����H��奬�y�@�U�ѡ^
�i��~��12�U�Ѥd�d��ADR

�p��ӥؼл�7�����C
�]�P��5.6�����C

5.6����x12�U�d�ѡת�6��7�d�U�����]�@���ҧ��^

�Ҹ�5��6���������T���ΥICSL3�d�U�������q���Q �ٷs�[�Y�]�F�����ɴڡC

2023�~1��31��l�}�{�ɪѪF�j�|���q�����i

2022 �~ 12 �� 21 ��AASLAN Pharmaceuticals Limited�]�����q���^�o�X�{�ɪѪF�j�|�q���]���q�����^�N����a�ɶ� 2023 �~ 1 �� 31 ��W�� 9 �I�b 3 Temasek Avenue �|�� , Level 18 Centennial Tower, Singapore 039190 ���Ҽ{�ðu���q�L�H�U�ѪF�Mij�G

�Mij 1�G

(i) �@���@�����q�Mij�A�W�[���q���k�w�ѥ��G

(A) �ӦۡG5,000,000 �������� 500,000,000 �Ѵ��q�ѡA�C�ѭ��ȩέ��Ȭ� 0.01 �����C

(B) TO�G10,000,000 �������� 1,000,000,000 �Ѵ��q�ѡA�C�ѭ��ȩέ��Ȭ� 0.01 �����C

�Mij 2�G

(ii) �@���@���S�O�Mij�A���q�{������´���{�j���M�ӫh�]�Y���q���ĤQ���׭q�M���z����´���{�j���M�ӫh�^�����ѷs����´���{�j���M�ӫh�] �O���q���ĤQ�@���׭q�M���z��´���{�j���M�ӫh�^�C

����Mij 2 �������G�綠�q��´�j���M�ӫh����ij�ק�ȭ���H�U���e�G

(a) �ܧ󤽥q���{�j���� 7 ���A�������q�ꥻ�A�H�ϬM�W�z�k�w�ѥ����W�[�F �M

(b) �C���q�g�ϥΧ�s�᪺�u�y�����q�k���N�������q�k���C

�ӳq�����ƥ��@������ 99.1 ���b���B�A��ij���ĤQ�@���׭q�M���z�����q��´���{�j���M�ӫh���ƥ��@������ 99.2 ���b���B�A��������q�L�ޥΨ֤J����C����󤤥]�t���H�� ���� 6-K �S���q�L�ޥίǤJ���q���� F-3 �����U�n���]���s�� 333-252575�^�B���� F-3 �����U�n���]���s�� 333-254768�^�B���� S- �����U�n�� 8�]���s�� 333-252118�^�M���� S-8 �W�����U�n���]���s�� 333-263843�^�C

�رi�j�C

�ثe��ڪ�����ݥ�������Ӳժ����ĦA�����k���h�G

EASI75 69% vs 24%(��Ӳա^�A�]������Ӳ�69%-24%=45%�^
IGA0,1 53% vs 15%(��Ӳա^�A�]������Ӳ�53%-15%=38%�^

Dupilumab 2�ӤT��.������Ӳի�
EASI75=36%
IGA0,1=28%

ASLAN004 vs Dupilumab

EASI75 45%��36%=125%
IGA0,1 38%/28%=135%

���סG�T���{�ɪ��D�n���СAASLAN004��Ĺ�LDupilumab �з����k25%��35%���ͶաC

��������������G
1.���~�G���Ѫ��ƾڥ��V�C
2.�|���G�ѩR10141925 �o���ɶ�:2022/8/11 �U�� 04:00:38
�ثe�䤣�����Ҥ��L���z�ѡI
(���~�G���Ѫ��ƾ�)EASI75������ASLAN004�u��Dupilumab40%�]69%/48.5�H�^�A��004�����һ��ȴN�D�`�B�D�`���C
----------------------------------------------------------------------�޿�Q�צp�U---------------------------------------------------------------------
���@TREK-DX���e�A���TREK-AD���Ѫ��ƾڴN���ļt�U���ʨM���F�A
�f�t���~�Ĥ@�u�ɿյ᤽��Dupilumab ��(111)�~�P���B(111�~���y�e�Q�j�Z�P��)�A
�ļt�ڥ����ݭnTREK-DX���Ѫ��ƾڡA
(TREK-DX���Ѫ��ƾڡA�O���ȷ�d�����Q���ʪ��B�Ϊ�)
�YTREK-DX�ƾڥ������e�N�Q�֡A�ȷ�d�]�|��TREK-DX�ƾڸӦ������ȥ[�b���ʪ��̭�(�ļt�]�|�{�P)�C
(���۫H�Ҧ��ļt����O���n��TREK-DX���Ѫ��ƾڥX��)
�YEASI75������ASLAN004�u��Dupilumab20%�H�W�A�ļt���N�i�H���ʨȷ�d�F�A
(�ڥ����ΦҼ{TREK-DX�|�Ѫ����\�Υ���)�A
(TREK-DX�Ѫ����\�G���Ӫ��C��H���O�DzΫ��f�w)
(TREK-DX�Ѫ����ѡG�ļt�H����[��ĵ�y�G�T�ι�H�����ϥ�Dupilumab�f�w)
�ļt�u�n���DASLAN004���ġB�ڬw�ϱ��v���B�MDupilumab��(111)�~�P���B�N���F�C
�ҥH�ȷ�d�̦��i��Q���ʮɶ��GTREK-AD�ƾڤ������TREK-DX�ƾڤ����e�C
(�w��U��j�j�@�P�Q��)
�x�ޤj

Dupilumab 2b ����300mg �|�g�@�w�A��IGA0,1��2�g�@针x300mg��70%.

�]Dupilumab �@�w��PK�i�W�L29�ѡC�^

ASLAN004 1A x�@�w�A600mg x6�H�]�䤤5�H��15�Ѫ���������A�^
�䤤2�H��28�ѧ�������
�䤤1�H�i�F25�ѧ�������
�䤤2�H�A�i�F18�ѧ�������
�䤤1�H�A�i��13�ѧ�������
Q4wx600mg IGA��Q2W ��50%�N��F�`�F�C
�H�W�ӤH�����C

�ѩR�j

���q������300mg 400mg��g���w�P400mg 600mg�|�g���w , �|�g���w�ثe�٨S���Ī��W�� , �D�ԬݬݦA��

����
�@�BASLAN004 2bxQ2W 0/1/2�wx300mg
���i��EASI,�ĥ|�g(��29��)

**��1b 400mgxQ1Wx6�H结�G�����B
65%x2�H
63%x2�H
61%x1�H
59%x1�H
����EASI �U��62%

�G�B2b 400mgxQ2W��
�B��29��
65%*4�H
63%x1�H
61%x1�H
����EASI �U��64%

�H�W300mg/400mg
�b�ĥ|�g(��29��)���ĥ|�w�B�b�Ĥ��g(��43��)�i�ɦ^�e��3%/1%�����t�D

EASI ��������71%.

ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb

Q2W�����ĥi���B�������|�W�V1b��8�g�v�������ġD

�ɥR�G�B
patents.google.com/patent/WO2020197502A1

��10
scx300mg �Įľ��Ͷչ�x6�H

2�H����������15�ѡB���̰���18��
2�H����������14��,
��14�Ѫ�START6�U���Ͷդ��l�ϼu15%,�Įľ�PK��85%.

1�H����������13��,
�֭p2��START6�ƶq�ϼu45%,�Įľ�PK��55%.
1�H����������12�ѡB�֭p3��START6�ƶq�@�ϼu90%,�Įľ�PK��10%.

�H�W�[��B�Įľ�PK�C��15%�ϼu�D�֭p3�Ѫ�90%���Įķl���B�ȯ����10%.

ASLAN004 SC�֤U�`�g���ͦ��v�j����30%(���J���骺�Ķq�̫�i�J��ު���v��30%.Dupilumab��50%)

ASLSN004���������ޤ��Ķq=1mg/L=1000ng/ml

��12b�ܭ��n�BSC �U���q��PK�ͩR�ϡD

IV10mg/kg: �R�ߪ`�g�B�魫�C���祴10mg.
60���祴�J��ޤ��Ķq10x60=600mg

70���祴�J�Ķq700mg

SC600mg:�֤U�`�g600mg

���]�i�J����Ķq50%(�ͦ��v),��L�Q����l���D

600*50%=300mg�i�J���

�B���ާA�魫�h�֡B���J�����Ķq�T�w�D

�@�ӱw��SC600mg,�i�J����Ķq��300mg
(sc�ͦ��v���]50%)�B�۷��� IV5mg/kg�Ӥw�D

�x�ޤj�B
IV 10mg/kg �i��������29�Ѫ����i�O���T���D

��SC 600mg ����������b���i��6�H�B��5�H���15�ѡB�t�@�H���8�ѡB

��12b��dupilumab vs aslan004
Sc pk �Ͷչ�
�z�i�h�ݬ�!

��12a�OIV dupilumab vs aslan004
Pk �Ͷչ�

2b �]�p��0/1/2�g�U�@�w�Ӥj��EASI�ܲĥ|�g��60%,�ѤU��10%~20%�i�Q��Ӱ��D�B
�a�᭱���w�ƨӸɡD

�ڹ�Q2W*400mg���H�̱߳j�B
Q4W��IGA ???

�ѩR�j

���ξ���魫���D �o�g�M�Q�O2020�~10��1����o---���׬O2021�~3��16��}�l �Ī��ʤO�Ǥ譱���q���i��S���x��
2b �{�ɤ~����SC�֤U�`�g

�����z�ת������A���M�Q�o���H�{���A�P Dupilumab �ۤ�AASLAN004 �i�H��{���C�� C through�A�]�� ASLAN004 �v�V IL-13Ra1�A�� Dupilumab �v�V IL-4Ra�C�b�餺�AIL-13Ra1 ���ƶq�j�j�W�L IL-4Ra ���ƶq�C
(�^�h��2021�~4�뤽�q²�� P 11�w���ѹv�V���P���骺���Ƽƾ� ( 60��:3�� )

�o�N����ASLAN004�ݭn���C����������A�]��ASLAN004 ���ĮľǯS�x���� ASLAN004 �P Dupliumab �ۤ�D�`���Q�A�ê��� ASLAN004 �C�뵹�Īv�����g�ʯe�f�]�p����ʥֽ����^����O

���j��ε��� 600mg �� ASLAN004 �Q�R�ߤ����� (10mg/kg) �ɡA����ܥX 100% ��������کM�b���īᤣ�� 1 �p�ɤ��������� STAT6 �C�ĤơC�o�ǮĪG�b�澯�q ASLAN004 ������W�L 29 �ѡA�����C�뵹�ĥi��O�i�H��{���C

ASLAN004 �� IL-4 �M IL-13 �H�����ֳt����]�i��ɭP����ʥֽ����M�L�өʭ��ݱw�̪��g���ֳt�w�ѡC

�H�W�ȨѰѦ�

�ɥR�G
1a 600mgx6�H�ɥR

��2�H�B�i���������28��
��1�H�B�i�������25�ѡD
��2�H�B�i���������18��
�̫�1�H�B�i���������13�ѡD

�b�H�U���}�W�B�i�U���ɮסD���U���Ͷչ�
patents.google.com/patent/WO2020197502A1

�g�L0/1/2�g�C�g�@�w�B���U�Ƥj�B�X�G�i�����������28�ѡD

300/400mg*Q2W �B���I�p�������������ġB�ר�O400mg.

Q4W,600mg�i�u

ASLAN004 1A ���d�Hx���@�w�����G�G�]���i����SCx600mgx6�H�ԲӨC�H���i�^

pSTAT6 �M RO �]IL13Ra1)���w�����G�p�� 2 �� 11 �ҥܡC
�R�ߤ� (IV) ���C�����G�]�� 2 �� 6�^
���� 0.1 mg/kg ���q����b 1 �p�ɤ���{�X�G����������� ASLAN004 ���޲z�C
�M�ӡA�o�خĪG�å�����ApSTAT6 �M������������ʤ��񦹫ᤣ�[�}�l�W�ɡC

0.3 mg/kg ���q���{�y�n�A��{�����������A����� 24 �p�ɡC �M�ӡA���� pSTAT6 �M������������A��í�w�W�ɡC

�ۤϡA�b 1 mg/kg ���q�����U�A�b�� ASLAN004 �v�����[��� pSTAT6 �M������������������� 1 �g�]�� 8 �ѡ^�C

�N���q������ 3 mg/kg �i�@�B�N�o�خĪG�����ܬ� 2 �g�]�� 15 �ѡ^�C

�o���`���Ͷզb 10 mg/kg ���q�����U�~��A�䤤��{�F�j�� 4 �g�]�� 29 �ѡ^����������C

���֤U (SC) ���C�]�� 8 �� 11�^�A���G���� 75 mg ���q����b�I�� ASLAN004 �� 24 �p�ɤ���{�X�G����������ڡC �M�ӡA�o�خĪG�å�����ApSTAT6 �M������������ʤ��񦹫ᤣ�[�}�l�W�ɡC

�M�ӡA�b �]SC�^150 mg ���q�����U�A�b�� ASLAN004 �v�����[��� pSTAT6 �M������������������� 1 �g�]�� 8 �ѡ^�C

�N���q������ 300 �@�J�i�@�B�N�o�خĪG�����ܬ� 2 �g�]�� 15 �ѡ^�C

��� 600 mg SC ���q�]�[������������G�C
�U����ܤF���� 600 mg SC ���Ī����ժ��魫�� PD ���v�T�G �� 2 �V ���ժ��魫�� PD ���v�T�G600 mg SC

PD:Pharmacodynamic �Į�
SC�G�֤U�`�g
IV�G�R�ߪ`�g

1�A55085(�s���^��70.6�]�魫������^��Full PD response to�]���������^15�ѡAPD lost by day 29)
��29�Ѯ��Įĺɥ��C�����O�k�s�C

2�B55088/65.3kg/15�ѡApartial PD to day 29
��29�Ѯɤ�����������.�������ĮġC

3�B55092/76.3kg/15��.PD lost by to day 29
��29�ѮɡA�ĮĬ��s�����O�k�s

4�B55095/82.3kg/����������8�ѡApartial PD to 15day
��15�ѮɡA�������ĮġC

5�B550958/76.3kg/15�ѡApartial PD to 29day
��29�Ѥ��������ĮġC

6�B55101/68.8kg/����������15�ѡC

�o�ǵ��G�i������W�[���ժ��魫�|�� PD ����ɶ����ͭt���v�T�C

These results may suggest that increasing subject weight negatively impacts on PD duration.

The results of the pSTAT6 and RO assays are shown in Figures 2 to 11. The results for the intravenous (IV) cohorts (Figures 2 to 6) suggest that the 0.1 mg/kg dose was able to achieve almost total receptor occupancy within 1 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. The 0.3 mg/kg dose performed slightly better, achieving complete receptor inhibition, which lasted for about 24 hours. However, pSTAT6 and % free receptor levels again steadily rise after this.
In contrast, at the 1 mg/kg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 3 mg/kg further extended this effect to about 2 weeks (Day 15). This general trend continued with the 10 mg/kg dosage level wherein complete inhibition was achieved for around 4 weeks (Day 29). For the subcutaneous (SC) cohorts (Figures 8 to 11), the results suggest that the 75 mg dose was able to achieve almost total receptor occupancy within 24 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter.
However, at the 150 mg dosage level, a sustained inhibition of pSTAT6 and %free receptor levels was observed for about 1 week (Day 8) following treatment with ASLAN004. Raising the dosage to 300 mg further extended this effect to about 2 weeks (Day 15). A similar result was also observed for the 600 mg SC dose.
The table below shows the influence of subject weight on PD for subjects dosed with 600 mg SC: Table 2�V influence of subject weight on PD: 600 mg SC

patents.google.com/patent/WO2020197502A1

ASLAN004��Q4W(�|�g�@�w)

�Y��ASLAN004 1a���d�H��Ʊ���
400�@600mg���ȥi���������12.5~13.5��
0/1/2/6/10/14�gx�X�p6�w

�H�U004����}�����B�����I�D
��28~42��(�ĥ|~���g)
��55~72��(�ĤK~�Q�g)
��83~93��(�ĤQ�G~�Q�|�g)

IGA0,1/IEASI90�����Ĥ���x���F���D

�ثe�Y���Ѫ���IGA0,1�������Ʋz�Q�B�̥i��X�{���D���N�i��b���Q4W�{�ɡD

Q2W���I�D�`�p�D

�ȷ�d�S�n�ѥ[��ڷ|ij

�ͪ��X�@�|ij
ASLAN Pharmaceuticals �޲z�h�N�X�u��2023�~1��9���13��b�ª��s Marriott Marquis �|�檺�����|ij�A�óq�L BIO Partnering �b�u�X�@���x�ѥ[�P���̩M��b�X�@�٦񪺤@��@�|ij�C

�n�b�����|ij�W���U�P�޲z�h�|���A�гX�ݦ��챵�C

�� 12 ���~�� LifeSci �X�@�٦���~��J����

ASLAN Pharmaceuticals �޲z�h�N�� 2023 �~ 1 �� 10 ��b�ª��s�ѥ[�������ʡA�ûP���c�����|��@��@�|ij�C

�Yģ�]�O�|���M�ļt�|�����v�N��ñ�q���v�X���γ\�V�O�Բӯu�ꪺ�ƾڤ~�൹�X
�w�����Y��������05/06���q���i����36�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A111/12/06�H�᤽���Ѫ��ƾڡC
���q��W���ƾڤF�A�ӥB�ҩ��@TREK-DX ���\�����v�ܰ��C
(�Y���~4��TREK-AD�Ѫ��ƾڥ��V�����|�ܤj�A�~�|��@TREK-DX)
(�ļt���DTREK-AD�Ѫ��ƾڥ��V�Ӥ�����??�n���TREK-DX�Ѫ��ƾڥ��V�A�~�ӥ[������???�޿褣��)

�b���@TREK-AD�����פ��ߡA�������ӧ@TREK-DX�A�Y�٥h�A�䦬�פ��ߪ��ɶ�???

���ӬO���ƾ��ҩ������|���o��
���{�ɷ|���\�~�W����
�ӥB�{�ɪ�����O�������B��U
?�|�O��b���R�a?�٬O�s�����D
���٬O���[�ݫݳo������j�A�j�P�h�ä��q�u�Q�����b0.5�H�W�A���H�W���W�L1���A��2023/3/26��A�W��A�H�}���Ȭw���v��ҡC�Ӥj

����ѥ��j���A�L�]�S��ۤ����A

���Ѥj�^�ɥL��۶^�A�{�b�ѻ��@���r

�޾��v�C�I�A

�L�̬һ⦳���q�~���A�������������O�q���A�o�O�L�̬��ۤv�Τ��q�������Ʊ�

�C�����q�����T���ΰѥ[��ڷ|ij������A

�ѻ��ҬO�ϦV�����A��������Ū�������P�A�O�H�O�ѡA

���M�ڤ]��ȷ�d�ܥ���
���Q�ѯu���O�D�Ԥ��o
���Ѽɶ^�A�p���ѳ����n
�ۤϦa��ı�o�ȷ�d���T�ꤽ�i�s�D�O�n��
�ܤ֤��q�٦��b�V�O�A�Ʊ椴�b�S�O�@�˱���

�ȷ�d���q�ť����n�T��

���Ѫѻ��@�w����

���Ѥ��ҥ~�ź٤w�n����s�Ĥ@��f�H

�{�b�ѻ�����10%�H�W

�u�O�з�韮�榬�ΪѡA�Φn�κ�
�зǪŴߤ��q

ASLAN Pharmaceuticals �ŧG�b Dupilumab �g�����S���ʥ֪��w�̤��i�� Eblasakimab ��s�z�ﭺ��w��
�ȴ����s�Ħ������q
2022 �~ 12 �� 15 ��P���|�ߤW 8:00�P7 �����\Ū
�ȴ����s�Ħ������q

�b Dupilumab ���g�窺�S���ʥ֪��w�� (TREK-DX) ��s���ϥ� Eblasakimab ������N�b�X�G�S���w���v����ܪ��w�̸s�餤���� eblasakimab

�Ӭ�s�N�b�_���۶� 75 �W�w�̡A�w�p�N�b 2024 �~�Ĥ@�u����o���u���G

��s����R���A�蠟�e���i���{���]�D�S���v�T

�Ӧ� TREK-DX �M TREK-AD ���ƾڥi�H��� eblasakimab �Ω�ͪ��Ǫ�v�M���g�窺 AD �w��

ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
ASLAN PHARMACEUTICALS LIMITED
Thu, December 15, 2022 at 8:00 PM�P7 min read
ASLAN PHARMACEUTICALS LIMITED
ASLAN PHARMACEUTICALS LIMITED
The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options

The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024

Study is fully funded with no impact on previously reported cash runway

Data from TREK-DX and TREK-AD could support the use of eblasakimab for both biologic naïve and experienced AD patients

2b �{�� 400mg xQ2W�A����

2b �ھ�ASLAN004 1b 400mg x8�gx�@�w���g�A�@8�w�AN=6 (2021/03/1������ơ^

ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb

1.����EASI���T⋯�]lb=2b)
�Ĥ@�g�]��8�� �^15%
�ĤG�g�]��15�ѡ^ 45%
�ĤT�g�]��22�ѡ^ 55%⋯�]TRAC���T�w�F�۹�C�I��73%�^

⋯⋯�@�@�@
2b �{�ɡA��23�ѡ��30�ѡA����

300mg �b���d�H1a�{�ɲ�8��IL13Ra1=0%�A��15��=30%�]���p��������O逹��13�ѡ^
600mg �b��8��IL13Ra1=0%,��15��10%(���p��������O逹��14�P4�ѡ^
400mg�b1A ��8��IL13Ra1=0%,��14�Ѧ�G���i�঳23%���A�]���p��������O逹13�P5�ѡ^

�h2b�{��400mg��������i�Ѳ�0�ѡ��27�P5�ѡA��G����IL13Ra1�i�O��0%���A�C
������EASI���T��62%�AEASI50���w�F80%⋯⋯⋯⋯EASI75���p>50%
�ѩ�80%���w�̤w�g�FEASI50�A,�h��29�Ѫ����ij̤j�i��N���d�b��27�P5�ѡA�p��8�g��11�g��TRAC�X�G�����b�C�ɡC
�b��29�Ѫ��ĥ|�w�I����ܧִN�^�_��������C

���סG2b ��29�Ѫ����ġAEASI�������T���p�u��3%���k�A�i�F��62%�C
�̦�����
2b �Ĥ��g�]36�ѡ^68%
2b �Ĥ��g�]43�ѡ^71%(���ӥi�ɨ����e�y�����ֶq���ġA�^��Ib�����ǡC

⋯⋯⋯⋯
1b
�ĥ|�g�]��29�ѡ^65%⋯�]��EASI50 �w�F83%�^
�Ĥ��g�]��36�ѡ^71%⋯�]�۹�C�I�AEASI75��67%�^
�K�K�K�K
1b=2b

�Ĥ��g�]��43�ѡ^73%⋯
�ĤC�g�]��50�ѡ^75%⋯�]�̧C�I�AEASI90���w�F67%�^
�ĤK�g�]��57�ѡ^74%

2.��L�������ġG
EASI50=83%
EASI75=67%
EASI90=67%

TRAC���T�G
aslanpharma.com/wp-content/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf

�|���G�ѩR10141925 �o���ɶ�:2022/11/12 �U�� 07:52:46�� 5764 �g�^��
Lebrikizumab 2b �P���Ī��F���t�קC��Dupilumab 2a ,����16�g���۪����ġC
ASLAN004 �C�g�@�w�A�e8�gEASI�U�����ijt�שMDupilumab�۪�C

�@�@�@�@

Dupilumab 2a N=110 QWx12�g Vs Lebrikizumab 2b Q2Wx16�gN��75:52

1�AEASI50
Dupilumab.//Lebrikizumab
�ĤT�g 55%//
�ĥ|�g 65%//52%
�Ĥ��g 85%�]�����I�^//
�Ĥ��g 85%//
�ĤK�g 85%//70%
�ĤQ�G�g85%//81%�]�����I�^
�ĤQ���g�X�X//81%

Dupilumab �i�P�ɪ������йvIL4/IL13�A�ҥH�b�Ĥ��gEASI50�N�F���I85%��Lebrikizumab�u�����IL13�γ���lL4�ҥH����ĤQ�G�g�~�F81%���I�C

�G�AEASI75
Dupilumab.//Lebrikizumab

�ĥ|�g 35%//30%
�ĤK�g �X//42%
�ĤQ�G�g62%//62%�]���I�^
�ĤQ���g�X�X//61%

�T�BIGA 0,1
Dupilumab.//Lebrikizumab

�ĥ|�g 18%//18%
�ĤK�g �@�@//30%
�ĤQ�G�g40%//41%
�ĤQ���g�X�X//43%�]���I�^
Lebrikizumab ���װT����O�į���t�A���ɶ��Ԫ���16�g�A���i�ɨ�IGA0,1�����ġC

www.nejm.org/doi/10.1056/NEJMoa1314768
�Ϥ@ Dupilumab

www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg

�ϤG�����G Lebrikizumab

aslanpharma.com/news/?cat=publications

ASLAN004 1b mITT �U�����Ь��b�Ĥ��㤻�g���̨θ��I�C�B��赢�LLebrikizumab ��16�g���ƾڡC

�H�W�ɥR�����C

��Lebrikizumab�]�L�k�����ʪ�IL4/IL13�G�^ ���n���г̨θ��I�j�h�X�{���12��16�g�C

www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de

Lebrikizuma 2�ӤT���{��,�C��g���Ͷչ�(2022/03/30)---Almirall ���q(�ڬw�ϾP�⤽�q)
��峄�P��:4.5���ڤ�

�D�n����:EASI75//IGA0,1
���n����:EASI90
//Pruritus NRS ≥4-point improvementa
from baseline
//Sleep loss NRS ≥2-point improvementa
from baseline
//Quality of life: DLQI ≥4-point improvementa
from baseline
---------------------------------------------------------------------------
���ASLAN004 1b MITT �ϫ�,��ASLAN004 2B �{�ɵ��G�|�󦳫H��.
�ڭ̫e�T�g�Ҥj�T����]�������ʪ�IL4/IL13�T���ǻ�,
�ĥ|�g���Ͷ����|�MLebrikizumab ���լ۪�.�]��ASLAN004�C�G�g�i��ȧ�������7�Ѫ������ʪ�,
���]�eASLAN004��3~4�g,�w�j�T��Ӫ�50%,�B�ͪ�����TRACC�w���ܩ��I(�̰�����80%).
�ĥ|�g��ASLN004 2B ���p��pLebrikizumab �b(���{)�������ꪺ���p�U,�U���Я�v�B�԰�,�F��������.

�̫�p���q�ҹw������(IGA 0,1)8% ����Dupilumab 2�g�зǪv�����|��.

�ؼл��p����:4~7����/�Ѿ��|��

�x�j��|�ֽ���D�����a��@�����ײ���ʥֽ����w�̡@�`����5�j�g��

�x�j��|�ֽ���D�����a����v���ܡA�����ײ���ʥֽ����w�̦�5�j�g���A�������ܦ��u��g���ڡv�C

1. �o�G��s���i���X6���H�W�����ױw�ֽ̥��b�@�Ѥ��o�o�W�L12�p�ɡA����o�o��57%�w�̷P���g�C
2. �h�G��s���X�W�L75%�����ײ���ʥֽ����w�̷|�P�줤�צ��Y�����k�h�P���A�C
3. �y��G��s��ܬ�4���w�̦b�L�h�@�g�ܤ֦��@�ѥֽ��y��´�G�άy��C
4. ���v�G��s��ܥb�Ʊw�̦b�L�h�@�g�ܤ֦��@�Ѻίv����v�T�C
5. �����G��s���2�W���ײ���ʥֽ����w�̤��N��1�W�A�C�Ѥ��Ш���e�f�g���ҭW�A25%�w��ı�o�L�̪��e�f�����A�Ʀ�30%���w�̦]���Ө��ۥ��j���߲z���O�ӳ��J�~�{�C

���F�H�W��5�I�~�A�ֽ��|�y��β�´�G���w�̷P�������A�Q�n�B���ۤv���w�����קK��L�H���鱵IJ�C

�x�W����ʥֽ����w�̡@�ͬ��~��լd

���a����v���ɡA���~�w��x�W����ʥֽ����w�̶i�檺�ͬ��~��լd�]�o�{�������G�A���R150�즨�H�w�̪��X�ݫ�A�o�{����ʥֽ����Y���v�T�U�ͬ����V�A�p��`���ʡB�u�@�DzߡB�H�����Y���A�f�p�V�Y���B�ͬ��~��V�t�C�Ҧ��w�̪��ίv�~�賣���n�A�������U�J�Ϊ���ҬO��H��1.5��12�A�B�u�@�Ͳ��O�]���v�T�A4�W�w�̴N��1�W�S�u�@�A���~�v�����ꥭ����7���C�����S���J�A75%�w���ٷ|�����Dz����k�B���d���~����L��k�A��O�[���w�̪��t��C

�����ײ���ʥֽ����v���T����

���a����v���ܡA�����ײ���ʥֽ����v�����T�����F�Ĥ@���q�`�|����ij�w�̨ϥΨŲG�B�O�㾯�Υ~�����T�J�Ī��M�ܲ�´�i�Ī��A��52%���w�̤����N�~�����T�J��g������ĪG�A�B�����ϥΫ�|���ϥֽ��������Ƨ@�ΡC

�ĤG���q�`�|�ϥΧK�̧���ĻI�ηӥ��v������k�A�e�̷|�y���ֽ����`���P�P�k�o�A��40%���w�̷P�즳�Ƨ@�Τ�63%�w�̤����N�K�̧���ĻI��g������ĪG�F��̦�60%���w�̤����N�ӥ��v������ĪG�C

�ĤT���h�ϥΤF�K�̽ո`���ӱ���o���ιL�Ӥ����A�������ϥΧK����i��|�v�T�x�B�ǥ\��A���@�w������G�ˬd�C�b�ϥΧK�̽ո`�����w�̤��A����53.4%����ҡA�f�p�Q��v�k��������}�C��8��������ʥֽ����w�̹��v���ä����N�A��4���w�̧�L5�ӥH�W��v�C�ӳ̷s���ͪ��s�����M���ġA���@�w�ݭn28000�A��w�̨ӻ��O�@�����p���t��C

��g���ڡG�{�Ѥ����ײ���ʥֽ��� - Heho���d
heho.com.tw/archives/28443

�ѥH�U������c(��R���),��ASLN 100�d�ѥH�W����
2022Q3 VS 2021Q1(�]�P4����/��) �έp

21,750�d�� VS 27,000 �d��

��W: 5,250�d��,
��W�����c����5,250/27000=19.4%,
��W���ѥ�5,250/70,000=7.6%

�䤤�R�W�̦h���O :
TANG CAPITAL MANAGEMENT LLC 5,654,925
CITADEL ADVISORS LLC ��2,000,000
--------------------------------------------
�䤤��W�̦h���O
ORBIMED ADVISORS LLC 2,520,000
LOGOS GLOBAL MANAGEMENT LP 2,300,000(���)
MANGROVE PARTNERS 2,178,063(���)
LUMINUS MANAGEMENT LLC 1,753,800(���)
ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57(���)

whalewisdom.com/stock/asln

�@.2022//Q3 ������c��ASLN ����

TANG CAPITAL MANAGEMENT LLC 5,654,925
RTW INVESTMENTS, LP 3,015,987
VIVO CAPITAL, LLC 2,840,909
CITADEL ADVISORS LLC 2,665,139
TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075
MILLENNIUM MANAGEMENT LLC 1,589,369
SIO CAPITAL MANAGEMENT, LLC 1,270,758
IKARIAN CAPITAL, LLC 820,455
SABBY MANAGEMENT, LLC 499,045
BARCLAYS PLC 471,270
RENAISSANCE TECHNOLOGIES LLC 365,800
WATERFRONT WEALTH INC. 360,500
MORGAN STANLEY 150,983
MYDA ADVISORS LLC 150,000
PLATINUM INVESTMENT MANAGEMENT LTD145,558

�X�p�� 21,750,000

�G.�|���G�ѩR10141925 �o���ɶ�:2021/5/19 �U�� 03:50:19�� 4214 �g�^��
2021�~3��31�� �b�����c���ASLN ADR ���Ӫ�

whalewisdom.com/stock/asln

RTW INVESTMENTS, LP 3,250,000
VIVO CAPITAL, LLC 2,840,909
ORBIMED ADVISORS LLC 2,520,000
LOGOS GLOBAL MANAGEMENT LP 2,300,000
MANGROVE PARTNERS 2,178,063

LUMINUS MANAGEMENT LLC 1,753,800
TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075
SIO CAPITAL MANAGEMENT, LLC 1,448,508
ASYMMETRY CAPITAL MANAGEMENT, L.P. 1,352,57
MILLENNIUM MANAGEMENT LLC 1,246,275
IKARIAN CAPITAL, LLC 1,224,516

SABBY MANAGEMENT, LLC 817,165
DAFNA CAPITAL MANAGEMENT LLC 677,500
CITADEL ADVISORS LLC 652,511
PLATINUM INVESTMENT MANAGEMENT LTD 514,984
KNOTT DAVID M 437,412
MONASHEE INVESTMENT MANAGEMENT LLC420,000
GOLDMAN SACHS GROUP INC 407,464
PARKMAN HEALTHCARE PARTNERS LLC 325,000
RENAISSANCE TECHNOLOGIES LLC 258,467
AFFINITY ASSET ADVISORS, LLC 200,000
MYDA ADVISORS LLC 200,000
CAAS CAPITAL MANAGEMENT LP 150,000
BOOTHBAY FUND MANAGEMENT, LLC 130,920
BARCLAYS PLC 128,586

�X�p ��27,000,000 , 38.5%(27,000/70,000)


�V�u�����o�@�u�O��F�v�I �ֽ�����v�ФT�ۤ��A�}�֬y�w
�� �v��
2022�~12��11�� �g�� �U��2:00

�׬y�s�D���O�̳��v�͡��x�_����

�o�o�A�O�A��F�I�o�O�V�u�ֽ���E���̱`ť�쪺��ܡA���M��|�ֽ�����v�I�ɽ����N���v�@�W5���k���]����ʥֽ����o�@�A��ߤ������o�A�L�k�J�v�A���u���}�֬y��A�ƦܥX�{�ˤf�o���B�y�w���ӵ߷P�V�����p�A���������s�¶ˤf�C��v�����A���ɥi�H�[�j�O�áB�קK��E�B�����L�ӭ쬰���@��h�C

����ʥֽ����W���A�ꤺ���E�[��A���֤p�B�ͱ`�]�k�o���@�A�L�k��o�R���ίv�A�믫���٪����p�U�A�i�Ӽv�T��դѪ������B�Dzߵ����ʡA�t�~�A�a���]�`�P���캡�����h

�I�ɽ�A����ʥֽ����O�x�W�`�����ֽ��e�f�A�O�@�ئh��]��Ǫ��o���e�f�A�D�n�O�ѥ��ѩʧK�̽ո`���`�Ϊ��֤��b�ձ����թҤް_�C�ھڲέp�A�x�W���W�L200�U�W�w�̡A�ܦh�H�q������ɴ��N�}�l�o�f�A���F�Y���k�o�a�Ӫ����A���~�A�����B�C�l�Τ��еo�@�y�����ֽ��a���ơA�]�����v�T��w�̦۫H�B����ΤH�����Y�o�i�A���_�o���S�ʤ������f�͹�v�����h���ݡA�Ʀܲ������O�P�t�������C

���E���N�����w�̦]�ⳡ���j���f�_�Ӥ����P�H����A���[�U�Ӻt�ܬ������ê�A�[�W������A�סA�b�D�ǤΨD¾�L�{���W�W�I���C

�I�ɽ���X�A����ʥֽ������Φ��M��j�]�������A�����O�u���̻֫ٯʳ��v���O�A�ֻE�J�կʳ��B���g�Q�i���������F�䦸�O�u�K�̲ӭM�L�פ����v�A���S�w�K�̲ӭM�H�΢�ӭM�L�׬��ơA�N�|�y���ֽ��o���A�Φ��x���B�o�o�B��h���{�ɪ��{�C

�ȱo�`�N���O�A�I�ɽ廡�A����ʥֽ������f�_�����|�H�ۦ~�֦Ӧ��Ҥ��P�A�b����Υ����ɴ��A�f�_�D�n�����b�y�B��y�ν��\�F�~�����j���p�ġA�h�b�|���s���B�X�{�C�ʭa�~�Ưf�_�F��F�C�֦~�Φ��H�A�ֳ����f�w�i��|�n�ण�A�_�o�A���j�h�|�����Χ��ܫ��A�A�Ʀ��ܦ��Y���������f�_�Υ����ʻ��ׯf�_�C

�I�ɽ��ij�A�������w���N�屵���v���A�o�f�ɥt�i���q���šB�q���}�l�A�çQ�Ψ�L�ƪ��ಾ�`�N�O�H�K��ˡA���`�h�`�N�O�áB�קK��E�λ����L�ӭ쵥���@��h�F�ܩ�ൣ�ΫC�֦~�A�b�߲z����������o�S�O�`�N�A���O�C�K�����J�{�A�άO�D�ǡB�dzƦҸչL�{�������O�����i��IJ�o�A���H�Ī�����B�ﵽ�f�p�~�A���n�ɤ]�i�M�D�߲z�԰Ө�U�A�άO���A�X�覡��o�������O�A���O�A�׹B�ʡB�W����гy�ʪ��𶢬��ʩΥ[�J�P��������ɤ߱����C

�Ӥ��ӷ��G���M��|

�ѧN

�i�峹����е����X�B�j

-~B/aD0yMDA7dz02NzA7YXBwaWQ9eXRhY2h5b24-/s.yimg.com/os/creatr-uploaded-images/2022-12/3dbc4bf0-76d7-11ed-bbfc-88e626aa2a99

Lebrikizumab �G�u(��Dupilumab�ϥθg��)��-����AD �T���{��120�H,�Y�N�}�l.�w�p12�Ӥ맹��.

�w���G16�Ӭ��ꦬ�פ���:

ASLAN004 �G�u(��Dupilumab�ϥθg��)��-����AD ,�G��, �w�p12�멳�����Ĥ@�ө۶�.

�H�W�G���{�ɴX�G�P�ɩl

---------------------------------------
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3

���j�B
whalewisdom.com/stock/asln
����1000�d�Ѫ��j�ѪF�k�H��7�Ӥ��q�D

�L�̪��g�z�H�|�MASLN���q���H�k��
���u���?

���|����儍!
�D��/���ƽ��v�b���ߤj�F�D

��p���Ѫ���b�L���T�ƾڥi�Ѥ��u!

�o�a���q�C���ѥ[��ڷ|ij��A

�Ϊ̤����Ѫ��T���A�q�S�n�Ƶo�͹L�A�ѻ��q�����������A���O��^�άO�w�^����^�A�Pı�O�Ӫ��Y���q�ACEO �N�O�֥]�նR�Ž�Ū��A

004 2b��B�������ƾڦp�G�����A

��l�j�ѪF�@�w�|�����D�A�ѻ��S�b���v���C�ɡA�j�ѪF�̲@�L�@���A�L�����@�L�ʧ@�A�N�O�綠�q�@�L�H�ߡA

�ڹ綠�q�]����Ʊ�A�N���R�ֳz�A��������̡A

Aslan004 2b �q���δ���G�̾�Dupilumab��Lebrikizumab 2b,ASLAN004 1b
1.400mg/Q2W
EASI75 69%
IGA0,1 53%

2.400mg/Q4W
EASI75=69%*93%=64%
IGA0,1=53%*75%=40%

IGA0,1���IJq��
400mg/Q2w//53%>300mg/Q2W//49%>
600mg/Q4W//47%>400mg/Q4W//40%>
���组15%
,���Ѫ��H�W����40%.

���q�U���i���ߦ��פ��߮ɶ��I�A����������i�Ѫ��ƾڮɶ��G
1.05/06���i����36�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A111/12/06�H�᤽���Ѫ��ƾڡC

2.06/28���i����39�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/01/28�H�᤽���Ѫ��ƾڡC

3.07/13���i����42�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/02/13�H�᤽���Ѫ��ƾڡC

4.07/15���i����43�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/02/15�H�᤽���Ѫ��ƾڡC

5.08/01���i����45�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/03/01�H�᤽���Ѫ��ƾڡC

6.08/23���i����65�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/03/23�H�᤽���Ѫ��ƾڡC
(�Ѱ�)

�����G
���~5��6��A���q���i�w�}�F36�ө۶Ҥ���(�W�L�������S�һݱ���)�A
���]��2�Ӥ�ө۶�(�z��)�A�Y7��6��}�l�v���C

�A��4�Ӥ�v���A�h11��6�骺16�g�v�������C

�A1�Ӥ��ƾ�z�A�]�N�O����(12��6��)�H��i�H���S�����ƾڡC
(�޲z���h�w�x�����ƾ�)

�U��i�H�}�l�[��ѻ������{�F�C

�@�BLebrikizumab 2b ��-���gAD x16�g�v��

www.clinicaltrials.gov/ct2/show/results/NCT03443024

125mg-Q4W//250mg-Q4W//250mg-Q2W//��Ӳ�

1.EASI 75�]%�^
43.3//56.1//60.6//24.3

2.IGA0,1�]%�^
26.6//33.7//44.6//15.3

�C�|�g�@�w�@250mg vs �C2�g�@�w250mg
1.EASI75 56.1/60.6=93%
2.IGA0,1 33.7/44.6=76%

Lebrikizumab 2b ���|�g�@�w�bEASI75�����Ĭ��G�g�@�w93%�]�e16�g�v���^
Lebrikizumab 2b ���|�g�@�w�bIGA0,1�����ĥu���G�g�@�w��75%�C�]�e16�g�v���^

�@�@�@Lebrikizumab ph3 17��52�g�v��.�b4�g��2�gEASI75&IGA0,1���Įt���h�C

�G�BDupilumab 2b �|�g�@�w vs �G�g�@�w

www.clinicaltrials.gov/ct2/show/results/NCT01859988

300mg-Q4W//300mgQ-2W//��v
1.EASI75 49.2%//53.1%//93%
2.IGA0,1 21.5%///29.7%//74%

�T�AASLAN004 2b �|�g�@�w vs �G�g�@�w �����Įt���H�H�H

�]�\����W�zLebrikizumab 2b��Dupilumab 2b �|�gVs �G�g���Įt��

�bEASI75 �t��93%
IGA0,1 �t��75%

�ֽ�����v�ϥΤ@�ث��[�������覡�GEASI�����A�ΥH�p�ⲧ��ֽ������Y���סFEASI���ƶV���V�Y���CEASI-50�N���Y���קﵽ�@�b�BEASI-75�N���Y���קﵽ�C�����A�H�������C

�H�ڭ̪��{�ɸg��A
1.�F��EASI-50(�Y���׭��C�@�b)�A�w�̸�a�ݴNı�o�ĪG�ܦn�A�q�`���N�״N�ܰ��F
2.��EASI-75(�ﵽ�C����)�|ı�o�ĪG�D�`�n�Aı�o�����ͤF�A�P�E���s�F

3.EASI-90(�ﵽ�E��)�|ı�o�X�G�n�F�A�֧���ͷ����b���C�Y�N�v���ĪG�q�ơG

www.dr-skin.com.tw/health/view/240
����ʥֽ����йv�Ī��u���ת��v�G���ġB�Ƨ@�ΡB�ϥΤ覡�B�O�θѪR

���j�A�ڤ]�{���w��50%�H�W��16�g����w�����A���H�ѻ������{�ӬݡA�٬ݤ��X���ƾڦ��n��n�j������H~�ӤH�P�_�A�����Ѳ��i�X���Ѧ�~~~~���j�A
ASLN ���q���ӥu�����Ѫ����ƾڡC

�p��i�j�Ҧ��A�ܤ֦���50%����16�g�v���C

�|���G�ѩR10141925  �o���ɶ�:2022/12/2 �W�� 06:32:10
�Q�߶Ȩѿ����ɡD�i�W���U���D ��L�p11��²�����e�D �D���H�ݨ�ASLAN004�T���dzơB ���G�N�O400�H���{��

�����G
1.�]�N�O2b �{�ɴ����ƾڸg���q�����T�{�O���V�L�~�A�~�|�Q�ݨ�ASLAN004�n���T���dzơC

2.���~5��6��A���q���i�w�}�F36�ө۶Ҥ��ߡA ���]��2�Ӥ�ө۶�(�z��)�A�Y7��6��}�l�v���C �A��4�Ӥ�v���A �h11��6�骺16�g�v�������C �A1�Ӥ��ƾ�z�A
12��6��H��i�H���S�����ƾڡC(���A�ݨӡA�������i�ƾڴ��e1�P���X�ӤF)

(�޲z���h�w���D�����ƾڤ��e�A�D���H�~�|�ݤT���dzư��D)
�U��i�H�}�l�[��ѻ������{�F�C

�ѩR�j

�ȷ�d004�T���A��400�H�{�ɰ��dz�

�O�_�N��2���{�ɤw�L���D��

�i��|��2���������i�ܡA�ѨM�ѻ������C��1�����M��

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

�Q�߶Ȩѿ����ɡD�i�W���U���D
��L�p11��²�����e�D

�D�u�H�ݨ�ASLAN004�T���dzơB
���G�N�O400�H���{��
(�ӤH�ɥR�G�@��O2�ӤT���{�ɡB�B�[52�g����������B�t�i��l�[�QTCS�~���ĻI�@���T�J�T���{�ɡB�H���ӽЬ��ꪺ�ĵ�)

CBO
���}�l��,�S�ťh�H���q��5��6�餽���ֿn36�Ӧ��פ��ߦ���(�W�L�������i���S�һݭn��)�A
���Y��6��20�馬������̨ö}�l�v���A
�g4�Ӥ�v����Y�O10��20��A
�A1�Ӥ��ƾ�z�Y�O11��20��C
�Q��(11/21)���q���i�N�b�ì��ѥ[�����O���|ij(11/29~12/1)�C
(���n���ݤӲ`�A�]�u��CEO�h)
�a��004�����ƾڡA�άO���ƾڤ]�n�A���������R�v�M�a���A�{�ҡA�ѷ�~�����|�X�Y�ѡCASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY.

A replay of the fireside chat will be made available on the Investor Relations section of ASLAN��s website and can be accessed directly at this link.

Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule a meeting.

ASLAN 2b����(�ɥR)
��0�� EASI28
��21��
����组����EASI=14��(��50%�^
���组����EASI=25��(��12%)
�[��G�C

www.nejm.org/doi/full/10.1056/nejmoa1610020
Dupilumab 2�ӤT���{�ɡA�ϤG�A�U�gEASI�U�������ͶչϡC

��Ӳեu���w衞�����w�̡C

�b�ĤT�g�����Ĭ�12��15%�A�������U����12�g33%�C�]���w��衞���̥禳AD��¡��O�A��������20%��18%�^

�ӥ�Dupilumab���դ��ިC�g�@�w�ΤG�w�A�b�ĤT�g���Ĥw�U����45��50%EASI
�ĤQ�G�g�����I����������70%�C�]�������ȭ�70%�@45��50%=25%~20%)

�b�ĤT�g�ɥ�Dupilumab�۹�󥴦w衞���կf���󻴬�35%�j�A�ҥH��¡��O�z���j��w衞���աC

ASLAN004 2b�e�T���i��������IL/IL4���21��A���ᦳ22��27��i��L��������p�A��������w衞���ժ���¡��O�i��C
����28�饴�ĥ|�w�N���W�Φ���������F�C

�[��T�C

�pASLN004�����Z�o��lbX8�g�v��
�ͪ����Цb�ĤT�gTRAC�x���ܬ۹�C���ǡC
TRAC���MEASI�U���ͶլO��������������СC

��ĤK�g����凖�A��7��11�g�����w�A���O���C������TRAC�C

ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
P�A26

�H�W�O�[��α��z�ӨӡC��ڤ���2b�Ѫ��誾�C

www.nejm.org/doi/10.1056/NEJMoa1314768
�Ϥ@�ADupilumab ����

EASI50

75mg vs 150mg vs300mg vs��Ӳ� x�C�g�@�wx4�g

�ѹϤ@�i�[���A��30�Ѫ����� 300mg >150mg>75mg>��Ӳ�

�䤤300mg/150mg �b��15�骺p�ȴN�p��0�P05 �έp�W������t���C

75mg/150mg �C�g���ĦH��300mg���ܡA���q�����A�L�k�����ʪ�I4/IL13��T�ǻ��C
���ɥu�O���ķ|�����A�u�n�����ɶ��v���A�C���q�եi��ױN�l�W�����q�աC

Lebrikizumab �]���������p�A�����v¡��52�g�BIGA0�A1�|�A�W�[4%��5%�C

ASLAN004 0/7/14��U�@�w.�i���������21��AEASI50 �i�F��55%�A
�o�Ǥw�������̦b0��7�Ѫ��i�ण�����q�����A�~���ө����w��ӡA�ϼu���|���j�C

��4�w�b28�饴�w��A��ӳt�״N���ӫ�_�C

�ҥH004 2b ��16�gX9�wx2�g�@�w���ġA���p>=1b ��mITT 8�g�������ӬO�X�z�����C

�@�@.�@.�@�@�@�@�@�@�@�@�@�@�@�@
2b �w�����ġ]��缐EASI27.5, IGA=3 65%)�A����

EASI 75=73%~81% vs 24% (�M��Ӳծt�� 49%��57%�^vs Dupilumab 2b 61%
IGA0,1=57%~61%. Vs 15%�]�G�t�� 42%��46%�^vs Dupilumab 2b 43%

������Ӳծt���A�����u��Dupilumab 2b 30%�H�W�����|�A���Ī���f�A�Ī��]JAK����G缐�Ī��^���i��ʤj�C

�H�W�ӤH�����C

�t�~Q2 ������}�������ASLN ��֬�1400�d��ADR

�̤j�ѪFTang �ꥻ��ꤽ�q���p�[�X100�d��ADR

�s�[�Y�H�������Ѥ��ܡC

whalewisdom.com/stock/asln

Lebrikizumab 2b �P���Ī��F���t�קC��Dupilumab 2a ,����16�g���۪����ġC
ASLAN004 �C�g�@�w�A�e8�gEASI�U�����ijt�שMDupilumab�۪�C

�@�@�@�@

Dupilumab 2a N=110 QWx12�g Vs Lebrikizumab 2b Q2Wx16�gN��75:52

1�AEASI50
Dupilumab.//Lebrikizumab
�ĤT�g 55%//
�ĥ|�g 65%//52%
�Ĥ��g 85%�]�����I�^//
�Ĥ��g 85%//
�ĤK�g 85%//70%
�ĤQ�G�g85%//81%�]�����I�^
�ĤQ���g�X�X//81%

Dupilumab �i�P�ɪ������йvIL4/IL13�A�ҥH�b�Ĥ��gEASI50�N�F���I85%��Lebrikizumab�u�����IL13�γ���lL4�ҥH����ĤQ�G�g�~�F81%���I�C

�G�AEASI75
Dupilumab.//Lebrikizumab

�ĥ|�g 35%//30%
�ĤK�g �X//42%
�ĤQ�G�g62%//62%�]���I�^
�ĤQ���g�X�X//61%

�T�BIGA 0,1
Dupilumab.//Lebrikizumab

�ĥ|�g 18%//18%
�ĤK�g �@�@//30%
�ĤQ�G�g40%//41%
�ĤQ���g�X�X//43%�]���I�^
Lebrikizumab ���װT����O�į���t�A���ɶ��Ԫ���16�g�A���i�ɨ�IGA0,1�����ġC

www.nejm.org/doi/10.1056/NEJMoa1314768
�Ϥ@ Dupilumab

www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg

�ϤG�����G Lebrikizumab

�T�BDupilumab �T�� vs ASLAN004 1b mITT 600mg

�U�g����EASI�U���T�׫e8�g�۪�C�]�N�����۷��P�ɪ���IL4//IL13��T���IJv)

www.nejm.org/doi/full/10.1056/nejmoa1610020
Dupilumab �ϤG�C

ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
p�A21

�ڻ{��
�۶үf�H���{�p�i��

�άO�_�w�۶ҧ���

�����ҵL����

2b���������ƾڤ�������

�֨ӭӥ��V�������ƾڡA�^�}�j�a������A�����c�k�H�Ӥ��Τ��� !²���X§�Ӥ��q�V FDA ���� BLA �Ω�v���S���ʥ֪��Ī�
02-11-2022 ���L

��h����o�ӬG��
EMA ���� Almirall �� lebrikizumab ��R���v���S���ʥ֪�
28-10-2022

����s�ĥ��Y§�� (Eli Lilly) �w�V���ꭹ�~�ī~�ʷ��޲z�� (FDA) ����F lebrikizumab ���ͪ��s�~�\�i�ӽ� (BLA)�Alebrikizumab �O�@�إΩ�v�����צܭ��ׯS���ʥ֪� (AD) ����s�ʥղӭM���� (IL)-13 ���s��.

AD �O�@�� IL-13 �D�ɯe�f�A�䤤 IL-13 �ɭP�ֽ��̻٥\���ê�B��o�B�ֽ��W�p�M�P�V���P�ʡC Lebrikizumab ���b�H���˩M�O�B�C�����t�v�M���ĤO���X IL-13�A�H���� IL-13 ���ͪ��Ǯ����C

�Ӵ���o��F ADvocate 1 �M ADvocate 2 16 �P�M 52 �g���G�H�� ADhere 16 �g���G������A�o�ǵ��G�O�H���B�����B�w������ӡB����աB���y�BIII ������ lebrikizumab �@����@���k�ûP�з��@�z�~�Υֽ����T�J�p�X�Ω�C�֦~�M���H�]12 ���ΥH�W�^�����ĩM�w���ʪ���s�C

�ھ� GlobalData ���ƾڡA�S���ʥ֪� (AD) ���������ȹw�p�N�q 2020 �~�� 64 �������W���� 2030 �~�� 7 �ӥD�n������ 168 �������A�ƦX�~�W���v (CAGR) �� 10.1%�C

BRIEF�XLilly submits BLA to FDA for atopic dermatitis med
02-11-2022 Print

MORE ON THIS STORY
EMA accepts Almirall��s filling for lebrikizumab in atopic dermatitis
28-10-2022

Lilly and Almirall��s lebrikizumab impresses a year in to eczema trial
07-06-2022

Lebrikizumab has significant impact on atopic dermatitis severity
12-04-2022

OTHER STORIES OF INTEREST
Under geopolitics and market rout, Chinese biotechs center on data quality and survival
09-11-2022

AI firm Insilico could pocket $1.2 billion in Sanofi tie-up
09-11-2022

Broader label to support greater US growth for Libtayo
09-11-2022

RELATED COMPANIES
Eli LillyArteaus TherapeuticsLilly
RELATED DRUGS
lebrikizumab
US pharma major Eli Lilly has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lebrikizumab, an investigational interleukin (IL)-13 inhibitor for the treatment of moderate-to-severe atopic dermatitis (AD).

AD is an IL-13 dominant disease in which IL-13 drives skin barrier dysfunction, itch, skin thickening and susceptibility to infection. Lebrikizumab is designed to bind IL-13 with high affinity, slow disassociation rate and high potency to inhibit the biological effects of IL-13.

The submission is supported by the ADvocate 1 and ADvocate 2 16-week and 52-week results, as well as the ADhere 16-week results, which are randomized, double-blind, placebo-controlled, parallel-group, global, Phase III studies that evaluated the efficacy and safety of lebrikizumab as a monotherapy and in combination with standard-of-care topical corticosteroids in adolescents and adults (12 years of age or older).

The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData.

�����@�u�ظ����{�ɼƾڹF�� ���~��ӽЬ�����

�d����x�_2022/11/09

���� (4162-TW) �� (19) �餽�i�A�X�U�ظ����s�Ħw��o (ONIVYDE) ���զX���k�A�v���@�u�ظ��������y�ϯé��{�ɸ���A�D�n�P���n�������Ч��F������{�ɷN�q�A����N�i�@�B��z�ƾڡA�̧֩��~��V���� FDA ���X���ҥӽСC

�������ܡA���{�ɸ���O�ѱ��v�X�@��� IPSEN �Ӱ���A�N�w��o�f�t�����ī~ Oxaliplatin (OX)�B�~�F���� 5 Fluorouracil (5-FU)�B�Ѭr�� Leucovorin(LV) ���զX���k�A�åH�ثe�@�u�ظ����зDzզX���k�@�������ӲաA���׹�H���ಾ�ʯظ��ɺ޸����w�̡A�@ 770 �H�C

�ھڸ��絲�G��ܡA�D�n�������Ъ��`�s���� (OS)�A�w��o�զX���k����u��зDzզX���k�B���n�������Ф����L�c�Ʀs���ɶ��]����۪��ﵽ�F�w���ʤ譱�P�L�h�{�ɤ@ / �G���ƾڹp�P�C

�������ܡA�X�@�٦� IPSEN �N�|�⦹�����絲�G�A�f�t�L�h�w��o���ֳt�f�d���A�V���� FDA ����A���g�������ӽСA�̧֩��~�짹���A���ӦA����V�ڬw�B�饻�B�x�W���a�ϴ��X���A�ݨ��o���ҫ�N�|��o���{�O���C

�ڲέp�A���y�C�~�E�_�X 50 �U�W�ظ��ɺ޸����w�̡A����C�~�h�� 6 �U�H�A�ѩ󦭴����q�S���S�w�g���A�q�`�e�f�X���쨭���L�����~�|�Q�o�{�A�ثe���E�_�X���w�̤��A���� 2 �����H�s�����W�L�@�~�C

�ڤ]ı�o�}�����O���|ij,
������n�aCBO�h???��ӬO......Mr Stephen Doyle, CBO

CBO�}�l�����v�B���ʤF!�B

ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
ASLAN PHARMACEUTICALS LIMITED
Tue, November 8, 2022 at 8:00 PM�P1 min read
ASLAN PHARMACEUTICALS LIMITED
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.

Please contact your Jefferies representative to request a one-on-one meeting with management.

2022�~Q3�]���X�l

investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating

���~�e�T�u�禬�w�W�L2021���~�A���~�P�����87�������C���~��110�������C

Dupixent /Dupilumab ���:�ʸU����
USA(����)// ROW (��L�ϰ�)//�p�p

2022
Q1 1,325.6//484.8//1,810.4
Q2 1,582.1//509.7//2,091,8
Q3 1,824.0//506.1//2,330.1
Q4
�X�p4731//1500//623

2021
Q1 961.5 //301.4//1262.9
Q2 1140//352//1492
Q3 1256.7//406.2//1662.9
Q4 1348//426//1774
�X�p 4712.8//1486//6198.8

2020
Q1 679.0 174.2 853.2
Q2 770.4 176.6 947.0
Q3 851.2 221.4 1072.6
Q4 925.6 246.4 1172.0
�p�p3226.2 818.6 4044.8

2019
Q1 303.0 70.7 373.7
Q2 454.7 102.6 557.3
Q3 508.3 124.8 633.1
Q4 605.2 146.3 751.5
�p�p 1,871.2 444.4 2,315.6

2018
Q1 117.2 14.2 131.4
Q2 180.9 28.3 209.2
Q3 219.6 43.0 262.6
Q4 258.6 60.2 318.8
�p�p 776.3 145.7 922.0

2017
Q1 *******
Q2 *******
Q3 88.5 0.5 89.0
Q4 136.9 2.0 138.9
�p�p 225.4 2.5 227.9
2017/03/28 FDA�֭�W��

MOA

www.taiwan-pharma.org.tw/weekly/2166/2166-5-3.htm

Janus Kinases�]JAKs�^�ݲӭM���ï��A�ñN�ӭM���W���T���ǥX�A�b�ǻ����|���AJAKs�|�P�ϰT���ǾɻP������Ʀ]�l(STATs)�C�ĤƤά��ơA�ո`�ӭM��������A�]�A��]���{�A�v�T�y��ӭM�B��P�K�̲ӭM�\��CJAK������йv�X���ܭ���f�Ī��]targeted synthetic DMARDs, tsDMARDs�^�O��~�ӷs�o�i���Ī����O�A�g��JAKs�ո`�ӭM�T���ǻ����|�A����STATs�C�ĤƻP���ơA�i�ӧ���o�������A���{���Ī��L�k�F��v���ؼЪ��f�H�v���a�ӷs��ܡC�۸���ͪ��s�����ݰw���A�����ī~���S�⬰�f�A�뤩�A�f�H�ϥΧ�K�Q�C��ij�v���ɾ��PboDMARDs�ۦ��A�Ω�csDMARDs�X�֪v���ᤴ�����ﵽ�ɡA���ثe���ޤ��u����ij�ϥ�boDMARDs�A���F�v���ؼФ~�Ҽ{�ϥ�tsDMARDs�C�ثe�v�����ޤ���������JAK���tofacitinib�Bbaricitinib�ҫD��ܩʧ���JAK-1�A�䤤�P�ɧ���JAK-2�B3�|�ɭP�y��F�ӭM�]hematopoietic cell)�B����y�ͦ����]erythropoietin�^�����n�Ͳz���઺�T���ǻ��Q���_�A�i�@�B�y�������Ƨ@�ΡC

��ܩ�JAK-1����z�L�M�@�ʧ���A������C�]����JAK-2�B3�ұa�Ӫ��Ƨ@�ΡA���ꭹ�~�Ī��޲z���]FDA�^��2019�~8��16��̾�Fleischmann ���H�o�������絲�G�A�֭��ܩ�JAK-1��� upadacitinib�]UPA�^�Ω�v�������צ��~RA�f�H�C���H�����ĤT���w������Ӹ��笰��26�g�A�@����449����ժ̡A�ұw�����ʩ�RA�B�ϥ�MTXí�w�v���ܤ֤T�Ӥ�H�W�A�����ϥιL��LboDMARDs��tsDMRADs�W�L�T�Ӥ�A�B�b�v���ᤴ�����e�f���ʡC���ժ̸g�H���������T�աG�C��f�AUPA 15 mg�B�C��g�֤U�`�gadalimumab�]ADA�^40 mg�H�Φw�����աA�U�լ��~��ϥέ�B�褧í�w���qMTX�C���絲�G��ܡA�b�� 12 �g�������A�P�w�����դ���A�F��~�Ȥ�IJ�h���`�Ƨﵽ�FACR20�]American College of Rheumatology 20% improvement criteria�^���f�H��v�A����UPA 15 mg�P�w�����դ��O��71% �P 36%�]p��0.001)�A�B�b26�g���������w�����ըΪ����{�F�P ADA �դ���A�b��26�g�F��~�Ȥ�IJ�h���`�Ƨﵽ�F50%�]ACR50�^���f�H��v�A����UPA 15 mg�P ADA �դ��O��54% �P 42%�]p��0.001)�A�ҹF�έp�W��ۮt���C�w���ʤ譱�A���26�g�έp���󤣨}�ƥ�]AE�^���o�ͤ�ҡA�b UPA 15 �@�J�B�C��g�֤U�`�gADA 40 mg�P�w�����դ��O��64.2%�B60.2% �P 53.2%�A�e��յo�ͪ���Ҭ۷��CUPA����礤�X�{�����}�����H�P�V�]�p�G�a��疱�l)�B�ٻĿE�ï��]creatine phosphokinase, CPK�^�W�ɡB�R�ߦ����]venous thromboembolic event, VTE�^���D�C�ӥt�@�ӿ�ܩ�JAK-1��� filgotinib �]�b�ĤT���{�ɸ��礤�����v���������צ��~RA�f�H�a����۪��{�ɧﵽ�A�é�2019�~12��16�鴣�X�s�ĥӽСC

Upadacitinib�T���]�f�A�Ī��^JAK���
MOA

IL4+IL4Ra+IL13Ra1 ���ͫ�II�ƦX����A�A�ӴN����JAK1/2,IgE�U�媺�������l�C

IL13+IL13Ra1+IL4Ra���ͫ�II�ƦX����A�A�ӴN����JAK1/2,IgE�U�媺�������l�C

�H�W2�ӳ~�|���O�ѤW�媺IL4�BIL13�}�l�C

����JAK���͸������ġA�u��ϱ�Dupilumab �ʦ�IL4Ra ���T���ǻ������|�}�C

��ASLAN004���ĥi����f�A�Ī��A����IL4��IL13�T���ǻ���j�C

�@�@���y�p�P��35�������]�P���窺�f�A�Ī��^

IGA0,1

15mg 48.1% vs 8.4%�]�t��40%�^
30mg 62% vs 8.4%�]�t��54%�^

���C�g�@�w8�g�N�i�����X

IGA0,1
mITT 7/16=44%
(7+6)/(16+6-1)=61%
��]�P�U�D

EASI75=81%

�A�[9-16�g�B�C�g�@�w�B�D�n�v����uEASI>41 ���ڸs�D

�D��统AD�w�̥����Q�ư��D

............
004-1b mITT*8�g����

EASI75
11/16=69%... mITT
(11+6)/(16+6-1)=81%
�t�[6�Ӱ�u=EASI19���g�̡B����TRAc/��IgE

�h6/6���Ī�100%

�t�~3�H���_�B���]��֬�2�H�B

�ؼ�EASI75=81%
IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1�����ġD)

......16 �g�v��

�u�������|�B�p���q�Ҩ�����f�A�Į�

�U�Ħy�p�P��@2==004 �����G

1�ALebrikizumab ���AD�T���{�����ĥD�n����IGA0,1 ������Ӳա]16�g�^����y�p�P��45������(������R�v������R)
AD�@l 30%�]43%-13%�^//52�g�԰�������46%
AD�@2 22% (33%-11%)//52�g�Ԩ�����39%

2�ADupilumab ���AD3���㦩����ӲաA��AD�y�p�P��80������(���q������l40���y�߾P��x55%=80��������AD.)
Solo1 28%(38%-10%)//52�g�������լ�36%
Solo2 28%(36%-8%)//52�g�������լ�34%

3�AASLAN004 2b �{��16�gx�C�g�@�w80%�u��Dupilumab�]������Ӳա^
28%x180=52%�K73�������P��

ASLAN004 2b 16�gx�C�g�@�w�A���ij���f�A�ĤG�u
�����64%��15%=49%�]���T����Ӳշ|����8��10%�A����դ@��Ӳծt���԰���52%���k�^

�X�p��ASLAN004 �y�p�P�� 73�Q17��90������
⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯
4�AUpadacitinib�T���]�f�A�Ī��^�@�@���y�p�P��35�������]�P���窺�f�A�Ī��^

IGA0,1

15mg 48.1% vs 8.4%�]�t��40%�^
30mg 62% vs 8.4%�]�t��54%�^

........
004�[�W��L�A���g����_�L100�������y�ݾP��

�ҥH���~�����G�u�Ѫ���Q2���Ѫ��Ӫ��󭫭n�D

���j�B
2018/2019��Ӥ�󪺫O�K������2027�~.�ѩR�j

�U�C2�ʫH�A������S���N�q��

����
�Ҩ����e���|
2022 �~ 11 �� 3 ��
�¤����K�v�����R�O
�ھ� 1934 �~�Ҩ����k
�������s�Ħ������q
��� 1-38475 - CF#37122
_____________________
ASLAN Pharmaceuticals Limited �ھڳW�h 24b-2 ����ӽ�
�ШD�������e�¤������H�����O�K�B�z
�ư��b 2019 �~ 1 �� 9 �鴣�檺 6-K ���檺���󤧥~�C
�ھ� ASLAN Pharmaceuticals Limited �����z�A��
�H���ŦX�O�K�ӷ~�ΰ]�ȫH��������
�H���ۥѪk�A5 U.S.C. 552(b)(4)�A���q�]�ȳ���
�M�w�����}�C �]���A�q
�H�U�i�~�b���w���ɶ��q�����|�V�����o���G
�Ϫ� 10.1 �� 2027 �~ 12 �� 20 ��
���e���|�A�Ѥ��q�]�ȳ��ھ�
���v

����
�Ҩ����e���|
2022 �~ 11 �� 3 ��
�¤����K�v�����R�O
�ھ� 1933 �~�Ҩ�k
�������s�Ħ������q
��� 333-223920 - CF#35819
_____________________
ASLAN Pharmaceuticals Limited �ھڳW�h 406 ����ӽ�
�ШD�������e�¤������H�����O�K�B�z
�q 2018 �~ 3 �� 26 �鴣�檺 F-1 ����n�O�n�������󤤱ư��A
�g�ץ��C
�ھ� ASLAN Pharmaceuticals Limited �����z�A��
�H���ŦX�O�K�ӷ~�ΰ]�ȫH��������
�H���ۥѪk�A5 U.S.C. 552(b)(4)�A���q�]�ȳ���
�M�w�����}�C�]���A�q
�H�U�i�~�b���w���ɶ��q�����|�V�����o���G
�Ϫ� 10.5 �� 2027 �~ 12 �� 20 ��
�Ϫ� 10.6 �� 2027 �~ 12 �� 20 ��
�Ϫ� 10.7 �� 2027 �~ 12 �� 20 ��
���e���|�A�Ѥ��q�]�ȳ��ھ�
���v�G
�F�R����
���Ѻ޲z�줽�ǥD��

���]�G�u���ĹF��
���ӤT���@�u���|�[�J�C�g�@�w�D
�Y�p预��80%�u��Dupilumab
�h�@�u�Ī��y�ݾP��73�������N�ܦX�z.

预��ASLAN004��3���{�ɨC�g�@�w����
��uEASI31//IGA3=51%
EASI75=78% vs 15%(�t��63%)
IGA0.1=62% vs 10%(�t��52%)

�ҥH���q����G�u�{�ɬO�諸�D

�@�u16�gx�C�g�@�w75�H�i�H����D

�b�\�h�A���g�W

�b�a��SC(�֤U�`�g)

�C�g�@�w�����X�B�A���C�G�g�@�w(���ĬۦP)

�w�̤j���٬O���n�C�g�@�w�D
�C�g�@�w�n�O�B�P�˻���D

��004-1b mITT*8�g����

EASI75
11/16=69%... mITT
(11+6)/(16+6-1)=81%
�t�[6�Ӱ�u=EASI19���g�̡B����TRAc/��IgE

�h6/6���Ī�100%

�t�~3�H���_�B���]��֬�2�H�B

�ؼ�EASI75=81%
IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1�����ġD)

......16 �g�v��

�u�������|�B�p���q�Ҩ�����f�A�ĮġD

�ЦU��j�j

�g�H�� ASLN ���q

�n�D�W�@��75�H���@�ux�C�g�@�w��AD �{�ɡD

�������ij���f�A�Ī�
IGA0,1=64%-15%=49%
EASI75=80-24%=56%

AD �y�p�P��W��70������

�[��L�A���g>100��������

���Ĥj��@��!

(�b�w���P�������p�U)

�ץ��@l
Dupilumab �s���3300����/600mg�B���q�X�t��x80%=2660����/600mg���禬
�s�y����=2660*10%=266/600mg
0.45 ����/mg

���]ASLAN004 16�gx�C�g�@�w���@�u��
���ij���f�A��
IGA0,1=62%-10%(���组)=52%
vs
Dupilumab ������38%-10%=28%

52%/28%=186%

���]�C��q���ۦP3300����/4�w

ASLAN004�@ �u�Ī��i�P80�������i��

����400mg*4=1600mg...ASLAN004
��Dupilumab 600mg�h1000 mg

�����h�X1000*0.45=450����/�C��
16 �g������Dupilumab�h�X1800����

1800/24000(�~�����ĶO)=7.5%(17-52�g�i��_�ΤG�g�@�w/�|�g�@�w�D

80��x(60%-7.5%)=52�������b�Q
�ά۷�80*92.5%=73��������Dupilumab 销��(60%�b�Q)

���סG��ij ASLN004 �C�g�@�wx16�g���@�u�Ī��i�Ϧy�p销���26�����G�g�@�w�B���ɨ�73������

�G�u�ıN�D�`�֡D(�]ASLAN004. �O�@�u�D�O)

�GASLN ���q���N75�H���G�Ī��Ƚw�B
�אּ�@�u75�H�B���o����f�A�Ī��v�������ĵ��G�D

�T���W�[�C�g�@�w���{��(�Pdupilumab)

Dupilumab �s���3300����/600mg�B���q�X�t��x80%=2660����/600mg���禬
�s�y����=2660*10%=266/600mg
0.45 ����/mg

���]ASLAN004 16�gx�C�g�@�w���@�u��
���ij���f�A��
IGA0,1=62%-10%(���组)=52%
vs
Dupilumab ������38%-10%=28%

52%/28%=186%

���]�C��q���ۦP3300����/4�w

ASLAN004�@ �u�Ī��i�P80�������i��

����400mg*4=1600mg...ASLAN004
��Dupilumab 600mg�h1000 mg

�����h�X1000*0.45=450����/�C��
16 �g������Dupilumab�h�X1800����

1800/24000(�~�����ĶO)=7.5%

80��x(40%-7.5%)=26�������b�Q
�ά۷�80*92.5%=73��������Dupilumab 销��(40%�b�Q)

���סG��ij ASLN004 �C�g�@�wx16�g���@�u�Ī��i�Ϧy�p销���26�����G�g�@�w�B���ɨ�73������

�G�u�ıN�D�`�֡D

�GASLN ���q���N75�H���G�Ī��Ƚw�B
�אּ�@�u75�H�B���o����f�A�Ī��v�������ĵ��G�D

�T���W�[�C�g�@�w���{��(�Pdupilumab)

�U�Ħy�p�P��

1�ALebrikizumab ���AD�T���{�����ĥD�n����IGA0,1 ������Ӳա]16�g�^����y�p�P��45������
AD�@l 30%�]43%-13%�^//52�g�԰�������46%
AD�@2 22% (33%-11%)//52�g�Ԩ�����39%

2�ADupilumab ���AD3���㦩����ӲաA��AD�y�p�P��80������
Solo1 28%(38%-10%)//52�g�������լ�36%
Solo2 28%(36%-8%)//52�g�������լ�34%

3�AASLAN004 2b �{��16�g�G�g�@�w���q��8%�u��Dupilumab�]������Ӳա^
28%x108%=30.3%

ASLAN004 2b 16�gx�C�g�@�w�A���ij���f�A�ĤG�u
�����64%��15%=49%�]���T����Ӳշ|����8��10%�A����դ@��Ӳծt���԰���52%���k�^

�X�p��ASLAN004 �y�p�P�� 26�Q17��43������
⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯
4�AUpadacitinib�T���]�f�A�Ī��^�@�@���y�p�P��35�������]�P���窺�f�A�Ī��^

IGA0,1

15mg 48.1% vs 8.4%�]�t��40%�^
30mg 62% vs 8.4%�]�t��54%�^

to�t��j
�ڤ]�O���ݩ_�ݰ�
�u�O�ثe�N�O���n���a����A��ۤ���
�o�ˤ��|�v�T�ۤv�߱�
�γ\���Ѭ�M���\�F�N���o�@����]
�]�������Ѳ��u�O�@�ӯ��_���ӫ~!
���ɬݦn!
�^�ɬ��a!
1�~�e�A6�����ɭԻ��dzƼQ�F�աA�Ѫ��@�w���\�C
1�~��A0.35�����ɭԻ����q�@�w�����ݨ�ƾڡA�Ѫ��j���v���ѡC
���A�Ѫ����G�å��X�ӡA�ӭt�����C
6���g�R�A0.35�g��A���ܪ��O�H��-�l�����C�C��~~~~~~~~~~~�Q��9�I51���R�i70�U�ѡA�ѻ�0.365�������A��26�U�����A�x��830�U
���3�I40���R�i148�U�ѡA�ѻ�0.3405�������A��50�U�����A�x��1600�U
�o�ⵧ���O�浧�w���w�ɥ���A�n�R���H�n����a(�n�檺�H�n���R�a)�A�����n����ɶ��M����A
�{�b�O�ѻ�����C�I�A�ҥH�����ӬO���H�Q��C�ӬO���H�Q�R�C(�޿�)
���]���i��O����浹�k��C
�Ȥj,

���q�����զp�����]���Ĥ�סB�L�̬O���ƾڦb�⪺�M�a�B�ڥu�O�����պ�Ӥw�B
�]�Ʊ榳�_�ݡB�����ĤT�w��p�P�����ĤK�w��4-6�g���������w�ӥͪ����ЬOí�w�����|�ϼu�B�o�˫᭱��4�@9�w�����į��j��f�A�Ī������ļ�O�B���ɤ~��b�Ĥ@�u�Ī����j�T���Dupilumab, ��঳�ʻ��B�������P���O�D

���L�ݤFASLAN004���X16�gx�C�g�@�w���{�ɳ]�p�N�o�̤��q�����Ӽ����D

A+B=26+17 =43���������̰��P��
2023�Q�~�����ʥ��Ȧ���20-25������
�C��20-25��������ȡD
------------------------------
�L�H�����ӬO�ѩR�S���L�̧C���@��
���H�۩�嘞

9�I51���R�i70�U�ѡA�ѻ�0.37�������A��26�U�����A�x��830�U

���R�i�ȷ�d �ʤ�1�ѥ�

��

����w���~�����������ƾڡA�H�{�����ѻ��ӬݡA�ثe�����ƾڥi���٤W���F�i��;�ѷ�ͭn�h�I�@�ߤF�A���M�p�P�Ӱ��j�һ��o�@�ˡA���z��������A���٬O���ݦ��_�ݡA�ܩ�s��ʹN�ۦ�P�_�F�A�]�o��C���A���I�ۭt~�G缐75�HAD�{�ɸѪ����q��b2023�~�A���`�b�~���C

�ҥH295�H�AQ2�Ѫ����i�A���|���G缐�v����ơC

ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c

11������q�̷s²���I


�ӤH��
�@�B
_________________________
ASLAN004 2B 16�g����� (�C�G�g�@�w) 295�H
��u��(EASI26~28)

EASI75 69% VS 24%
IGA0.1 46% VS 15%

ASLAN004 ��T����u EASI�|�԰���EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10%
�������EASI�|�԰�,���ĤU��2~3%

���� : �p���q9/15�Ҽ���,�@�u������(�C�G�g�@�w) �i8% ��Dupilumab �w�b�����|�j.

�G�BASLAN004 2B 16�g����� (�C�g�@�w) 75�H
��u��(EASI26~28)

EASI75 73%~80% VS 24%
IGA0.1 57%~64%% VS 15%

ASLAN004 ��T����u EASI�|�԰���EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10%
�������EASI�|�԰�,���ĤU��2~3%

���� : �p���q9/15�Ҽ���,�G�u������(�C�g�@�w) �i��f�AUpadacitinib ���|�j.
.

�T�B�����w��

�@�u�Ī�47%�۹��Dupilumab���n,
�ѩ�G�u�Ī��u�����{�A����52�g���Ħ���O�A�԰��B�[�W��L�Ī��Ҷq�B��������Dupilumab1/3=80*1/3=26�������KA

�G�u�Ī�
46% ���n�۹��f�A�Ī��D
�̦~�����ۦ�AD �f�A�ĥi�P35�������B
�����������1/2������17�������i��...B

A+B=26+17 =43���������̰��P��
2023�Q�~�����ʥ��Ȧ���20-25������
�C��20-25��������ȡD

Upadacitinib AD �T���{�ɵ��G:

1.
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1)

��u EASI29(15mg)//EASI30(30mg)//EASI28(��Ӳ�)

��u IGA=4 46%(15mg)//47%(30mg)//45%(��Ӳ�)

clinicaltrials.gov/ct2/show/results/NCT03569293?term=NCT03569293&draw=2&rank=1

2.16�g ����

(1).EASI75
�����vs��Ӳ�

15mg 69.6% vs 16.3%
30mg 79.7% vs 16.3%

(2).IGA0,1

15mg 48.1% vs 8.4%
30mg 62% vs 8.4%

_________________________
�ӤH��
ASLAN004 2B 16�g����� (�C�g�@�w) 75�H
��u��(EASI26~28)

EASI75 73%~80% VS 24%
IGA0.1 57%~64%% VS 15%

ASLAN004 ��T����u EASI�|�԰���EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10%
�������EASI�|�԰�,���ĤU��2~3%

���� : �p���q9/15�Ҽ���,�G�u������(�C�g�@�w) �i��f�AUpadacitinib ���|�j.

-----------------------
3.AD-2/AD-3 没���}�{�ɵ��G���

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)
clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1

---------------------------------------------------------------------------------------

www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s004lbl.pdf
RINVOQ® (upadacitinib) FDA ������

ĵ�i�G�Y���P�V�B���`�v�B

�c�ʸ~�F�A�D�n���}�ߦ��
�ƥ�]MACE�^�M���Φ�

�������㪺�®�ĵ�i�A�аѾ\���㪺�B��H���C
• �Y���ӵߡB�u�ߡB�f�r�M�P�V�����I�W�[
���|�ʷP�V�ɭP���|�Φ��`�A
�]�A�͵��֡]TB�^�C�ϥ� RINVOQ �i�椤�_�B�z
�p�G�o���Y���P�V�A����P�V�o�챱��C����
�v���e�M�v�����������ʵ��֯f�F�v�����ʵ��֯f
�Q�ΡC�b�v�������ʴ��Ҧ��w�̪����ʩʵ��֯f�A�Ʀ�
��l���ʡB���ʵ��֯f���窺�w�̡C (5.1)
• �󰪪����]���`�v�A�]�A�`��
�t�@�� Janus �E酶 (JAK) ���s���ɭP�ߦ�ަ��`
�P����������`�������~�F�a���]�l (TNF) ���������
(RA) �w�̡C (5.2)
• ���� RINVOQ �v�����w�̵o�ͤF�c�ʸ~�F�C
�t�@�� JAK ���O�ڽF�M�����o�f�v��
RA �w�̤����s���P TNF ������������C (5.3)
• ������ MACE �o�Ͳv�]�w�q���ߦ�ަ��`�B
�ߦٱ��M�����^�P�t�@�� JAK ���s��
�P RA �w�̤��� TNF �������ۤ�C (5.4)
• ���� RINVOQ �v�����w�̵o�ͦ��Φ��C
�ͮ��B�R�ߩM�ʯ߮�몺�o�Ͳv�W�[
�t�@�� JAK ���s���P TNF �������������C (5.5)

WARNING: SERIOUS INFECTIONS, MORTALITY,

MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR
EVENTS (MACE), AND THROMBOSIS

See full prescribing information for complete boxed warning.
• Increased risk of serious bacterial, fungal, viral, and
opportunistic infections leading to hospitalization or death,
including tuberculosis (TB). Interrupt treatment with RINVOQ
if serious infection occurs until the infection is controlled. Test
for latent TB before and during therapy; treat latent TB prior to
use. Monitor all patients for active TB during treatment, even
patients with initial negative, latent TB test. (5.1)
• Higher rate of all-cause mortality, including sudden
cardiovascular death with another Janus kinase (JAK) inhibitor
vs. tumor necrosis factor (TNF) blockers in rheumatoid arthritis
(RA) patients. (5.2)
• Malignancies have occurred in patients treated with RINVOQ.
Higher rate of lymphomas and lung cancers with another JAK
inhibitor vs. TNF blockers in RA patients. (5.3)
• Higher rate of MACE (defined as cardiovascular death,
myocardial infarction, and stroke) with another JAK inhibitor
vs. TNF blockers in RA patients. (5.4)
• Thrombosis has occurred in patients treated with RINVOQ.
Increased incidence of pulmonary embolism, venous and arterial
thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)

�S���ʥ֪�
• 12 ���ΥH�W�魫�ܤ� 40 ����M
65 ���H�U�����~�H�G�}�l�f�A 15 mg �v��
�C�Ѥ@���C �p�G�S����o�������T���A�ЦҼ{�W�[
���q�� 30 mg�A�f�A�A�C��@���C (2.5)
• 65 ���ΥH�W�����H�G���˾��q�� 15 �@�J�@��
Atopic Dermatitis
• Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and
Adults Less Than 65 Years of Age: Initiate treatment with 15 mg orally
once daily. If an adequate response is not achieved, consider increasing the
dosage to 30 mg orally once daily. (2.5)
• Adults 65 Years of Age and Older: Recommended dosage is 15 mg once

Table 13: Efficacy Results of Monotherapy Trials at Week 16 in Patients with Moderate to
Severe AD
16���g�T������(��u����EASI29//IGA0,1=449%)---���ιL�ͪ������-����AD�w��

1.IGA0,1
�����VS ��Ӳ�
Trial AD-1
15mg 48% vs 8%
30mg 62% vs 8%

Trial AD-2
15mg 39% vs 5%
30mg 52% vs 5%

Trial AD-3( RINVOQ+TCS VS TCS)
15mg 40% vs 11%
30mg 59% vs 11%

2.EASI75
�����VS ��Ӳ�
Trial AD-1
15mg 70% vs 16%
30mg 80% vs 16%

Trial AD-2
15mg 60% vs 13%
30mg 73% vs 13%

Trial AD-3( RINVOQ+TCS VS TCS)
15mg 65% vs 26%
30mg 77% vs 26%

�f�A���ĬO����,�i���Ƨ@�Τӭ�.
ASLN ���q 9/15���]ASLAN004 �C�g�@�w���ĥi�P RINVOQ® (upadacitinib)���.
RINVOQ®�T���O-���ιL�ͪ������-����AD�w��

Trial AD-3 �� RINVOQ+TCS ,�įq���j.

9/15 R&D DAY
ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f

P.38
ASLN004 �۹��Rinvoq (upadacitinib)�f�A��--(�����j�Ƨ@�� ���I-) �ϥΰ��n���:

2B 75�H ,�i����c: TREK-AD QW(�C�g�@�w) 47%---�G�u�Ī�

Rinvoq (upadacitinib) ����5600����/��, ����Dupilumab 3300����/�� ��5600/3300=1.7��

ASLAN004 �G�u, �C�g�@�w*16�g���{�O�ΩMRinvoq (upadacitinib)����Ħ����i���۷����v���O.

www.goodrx.com/rinvoq

aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf
1A ���d�H���@�w SC(�֤U�`�g) 300mg/600mg �է�������u��7��. ��14�Ѧ�30%/10%���ϼu

���d�H���@�w IV(�R�ߪ`�g) 10mg/KG(60����600mg) �է�������30��

ASLAN004 SC�ͦ��v(���b���� �i�J�R���Ķq��v)�i�ण��50%.
DUPILUMAB SC�ͦ��v53%.

aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf
1A ���o�d�H���@�w SC 300mg/600mg �է�������u��7��. ��14�Ѧ�30%/10%���ϼu

1b SC 400mg/600mg �����w��,�̾�TRAC/IgE �ͪ����Хi�O4~6�g����,�B�q�ĤT�g�}�l�N�F�۹�C�I.

2b SC 300mg/400mg Q2w/0/1/2�g�U���@�w��q��4�g�_�C�G�g�@�w���14�g.�ͪ����к����b���ɦ����|,��4�g��n�A���i�ण�|�Ӧh. �G���ĥi��M8�g/1-�w��1b�۪�.

ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
p.24//p.25

�ӤH�q��: 2b
clinicaltrials.gov/ct2/show/NCT05158023
295�H

���ĴN�j������ 1bmITT

EASI75 69% VS24% (��Ӳ�)---�t��55%
IGA0,1 45.5% VS 15% (��Ӳ�) ---�t��30.5%(30.5%/28% DUPILUMAB=109%)

�]��2B �w��9�w ��1B 8�w. �������۷�.

�ˬO�G�u��16�g16�w, �~�����| EASI75 73%//IGA0,1 57%. �h7�w��������.

9/15 R&D DAY
ir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f

P.38
ASLN004 �۹��dupilumab �ϥΰ��n:
2B 295�H .�i�� TREK-DX Q4W(�w/4�g)57% /Q2W(�w/2�g)47%----�@�u�Ī�

2B 75�H ,�i����c: TREK-AD QW(�C�g�@�w) 47%---�G�u�Ī�

47%*65%(dupilumab ���_�v)=30.55%------�G�u�Ī�

�����멳�Ѫ��i�W�[�G�u�Ī�30.55%
+�@�u�Ī�47%~57% = 78%~88% ----
---------------------------------------------------
���q����N�p�W,�̦��ӼW�[�Q���ʻ���.

��2023/3��16~26��, �p��ԹL1����?�_�h�n���~

�|���|3�����Ѫ���,����p�Ұ������7*80%*88%=4.92����/��,6�뤽�G�ƾڥ]�P7*80%=5.6����/��

----------------------
�p2021�~2��24����p��3.52����/��,1800�U���� (3.52/4=88%)
ir.aslanpharma.com/static-files/8e211cfa-512e-4f27-b382-dea0efcc2e14

2021/3��1��줽�G�����Ѫ�

2021/3��4���]�P4����/��


9/15�s�D�`
ASLAN Pharmaceuticals �Ұ��{�ɭp���H��s Eblasakimab �b Dupilumab �g�����S���ʥ֪��w�̤����@��

ASLAN �p���� 2022 �~�ĥ|�u�׶}�l TREK-DX�]EblasaKimab �b Dupilumab eXperienced AD �w�̤�������^�A�H���� eblasakimab �@�����N�ͪ��s����w����ϥ� dupilumab �v�����S���ʥ֪� (AD) �w�̪����ĩM�w����

TREK-DX �N��s eblasakimab �b�����L dupilumab �v�����w�̤�����b�γ~�A�H�ɥR���b�i�檺 TREK-AD ����b�ͪ��ѯu���w�̤��i��
�ⶵ��s�����G�i�N�̥��Ԧ��ܩw�쬰�v�����צܭ��� AD ������ͪ��s��
------------------------------
(TREK-DX�Ĥ@��w�p�~���۶�//����(�_���w��2:1,���̦h25�۶ҭӤ���)
--��2023�~6�멳TREK-DX 75�H �Ѫ�//�P�ɤ��GTREK-AD 2B 295�H,�Ѫ����i)
------------------------------

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab
TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab, complementing the ongoing TREK-AD trial in biologic naïve patients
Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD
TREK-DX program is part of the Company��s existing operating plan and has no impact on previously-reported cash runway
Further discussion of TREK-DX will take place during the Company-hosted R&D Day on September 15, 2022
California and Singapore, September 14, 2022 �V ASLAN Pharmaceuticals (��ASLAN��, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile. ASLAN expects to enroll the first patient in the trial in the fourth quarter of 2022.

��In contrast to our Phase 2b trial in biologic naïve patients, TREK-DX will allow us to evaluate eblasakimab��s unique mechanism of action in a new patient population,�� said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. ��We believe that many patients previously treated with dupilumab can benefit from eblasakimab, and this data could support the use of eblasakimab in both the biologic naïve and experienced patient populations.��

The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company��s existing operating plan and has no impact on its previously-reported cash runway.

The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus.

��Dupilumab has played an important role in demonstrating the benefits of targeting the IL4/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to dupilumab, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,�� said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals. ��As we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that eblasakimab��s unique approach to blocking the Type 2 receptor may offer an effective treatment for dupilumab-experienced patients.��

ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023.

ASLAN��s management is hosting a Research and Development (R&D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click here for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical��s website at ir.aslanpharma.com/

����G�j���ӳ̷s����ASLN �����R�i���� �ؼл� 7~4 ����.

1.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals (ASLN �V Research Report) today and set a price target of $7.00. The company��s shares closed last Friday at $0.40.

H.C. Wainwright Sticks to Their Buy Rating for Aslan Pharmaceuticals (ASLN)

Oct 31, 2022, 06:15 PM

www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aslan-pharmaceuticals-asln?mod=mw_quote_news

2.
ASLN 12:29 10/28/22 Aslan Pharmaceuticals ended Q3 with $69M in cash, says Piper Sandler Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $4 price target on Aslan Pharmaceuticals shares.

Aslan is conducting the Phase IIb TREK-AD study of eblasakimab in ~300 moderate-to-severe atopic dermatitis with top-line data expected in 2Q23, and the company ended Q3 with cash of $69M, Tenthoff tells investors in a research note. Aslan is also planning a Phase II study of DHODH inhibitor farudodsta in skin autoimmune disease that will commence in 1H23, the analyst adds.

Read more at:
thefly.com/n.php?id=3605306

�ѩR�j�A

�p�G����~3��26��e�A004 2b����ƾڦn�a�A��z�έp��ƮɡA���Ӧ��N�߲z����

�Y�ѻ�������s�򯸤W1�����A�N���j�ѪF�Ϊk�H�w���{�P�Ӥ��q�A���@�A�W��C

�ڻ{���ѷ�_���^�ͪ����|�w�L�G��L�A���ɥu����{��

�ۤv�����q�ۤw���Ͻַ|�ϡA�j�a�u������

���j�A

�Ъ`�N�A���~3��26��e�Y�ѻ����s�򯸤W1�����C

�B�n����W���C

ASLN ���q��k
1�A��资
2.�W�[��ѹﴫADR��v�C

�ثe���q�A2b���Ѫ�资�Ƥ��G������b2023�~�ĤG�u�C
�K�K�K�K�K�K�K�K�K�K
�i��]�L�������i�C

����F���ɶ� 2022 �~ 10 �� 28 �� 07:00 | ��ƨӷ��G �ȴ����ķ~�������q

...
�I�� 2022 �~ 9 �� 30 ��A���q�H 6,890 �U�������{���B�{���������M�u�����������d���g�窬�p�F�w�p�� 2023 �~�����]�D
��s eblasakimab �bdupilumab������O���s TREK-DX �{�ɭp���g���F�S���ʥ֪� (AD) �w�̡A����b 2022 �~���e�۶ҲĤ@��w��
eblasakimab�b�ͪ����X���צܭ��� AD �w�̤��� 2b �� TREK-AD ���祿�b�i�椤�A�w�p�N�b 2023 �~�ĤG�u�ײ��ͤ@�u�ƾ�
�[�Q�֥��Ȧ{�t���S���M�s�[�Y�A2022 �~ 10 �� 28 �� (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN) �O�@�a�{�ɶ��q�B�H�K�̾Ǭ����I���ͪ��s�Ĥ��q�A�}�o�зs���k�H���ܱw�̪��ͬ��A���ѫť��]�ȺI�� 2022 �~ 9 �� 30 �骺�ĤT�u�׷~�Z�A�ô��ѤF�̪񤽥q���ʪ��̷s���p�C

���b�ĤT�u�סA�ڭ̴Neblasakimab�b���g����o�M���g�q���������P�@�ξ���X�F�\�h�s�����n���ѡA�H�λP��o�M�ίv�ॢ������ AD �w�̪���b�ﵽ�A�o�q�`�O�o�DZw�̡A�� ASLAN Pharmaceuticals ���u����x Carl Firth �դh���ɹD�C���ڭ̴��� 2b ���ƾڦb 2023 �~�� 2 �u�צb�ͪ��ѯu���צܭ��� AD �w�̤�����eblasakimab���D�n�ƾڡC�b�ڭ̱N�q TREK-AD �M TREK-DX �ͦ����s�ƾڤ��e�A�ڭ̥��b�q���b�i�檺��s�X�@���إߤ@�M�j���O�����ѡA�o�ǦX�@�N����~��i�ܡA�H���eblasakimab�㦳�@�������� AD ���t���ƪv������O�A�b 2 ���X�ʪ����g�ʯe�f���㦳�s�x���v����O�C��

2022 �~�ĤT�u�פΪ���~�ȫG�I

�̥��Ի����

8 ��A���q�P Belle.ai ñ�p�F�@���\�i��ij�A�Ω�b���y�h�ӯ��I�ϥ� belleStudy ™�Ʀr�Ϲ�����n��A�Ω� AD �����b�i�檺eblasakimab�� TREK-AD ��s�C����ϥΪ��ѨM��ץi�H�q�L�Ϲ�����зǤưO�� AD �e�f�Y���{�׵����A�ӧ޳N�N�� ASLAN ����i�@�B�[�j��b TREK-AD ��s������q���s�{�ǡC
9 ��A�b�� 31���ڬw�ֽ��f�ǩM�ʯf�Ƿ| (EADV) �~�פj�|�W�i�ܤF�T�i�����A�䤤�]�t���e���i��eblasakimab 1b ���������Ҹ��窺�ͪ��лx���B���Ĵ��q�M�w�̳��i�����G���q���s�ƾڡC�ƾ����eblasakimab���� AD ���U�媢�g�ͪ��лx���A�åB�o�ا@�Φb�̫�@�����ī���� 4 �� 6 �g�C����eblasakimab�v�����w�̦b�ίv��q���q�Meblasakimab�v���譱���{�X��ۧﵽ�P�w�����ۤ�AP-NRS�]�o�^�������C�A�b�Ҧ����q�ժ��K�P�v���L�{�������ﵽ�C�����i�b���q�������s�D�M�X�����������C
9 ��A���q�}�l�F TREK-DX�]EblasaKimab �b Dupilumab eXperienced AD �w�̤�������^�A�o�O�@����seblasakimab�bdupilumab���צܭ��� AD �w�̤����s�{�ɸ���C�Ӹ���]�A 16 �g���v�����M 12 �g���w���H�X���C�D�n���IJ��I�O��l���n�Y���׫��� (EASI) �����q��u��� 16 �g���ʤ����ܤơC���X TREK-AD ���礤�ͪ���l AD �w�̪��ƾڡA�ڭ̬۫H TREK-DX ��s�����G�b���ͪ��Ǹg�窺�H�s�i�H�Neblasakimab�w�쬰���צܭ��� AD �����ﭺ��v����k�C
���q�� 9 ���|��F��o�鬡�ʡA�޲z�h�b�|�W������s�Feblasakimab�}�o�p���C��_�j�� Feinberg ��ǰ|�� Peter A Lio �դh�M�����N�������j�Ǫ� Shawn Kwatra �դh�Q�פF AD �M 2 ���X�ʯe�f���s�X�{���������ݨD�B�v���e���M��b�����l����C�i�H�b���q�������������Y������쬡�ʩM�t�ܧ��ƪ������C
9 ��A���q�b�ڬw�ֽ��f�Ǭ�s��| (ESDR) �~�|���̷s�|ij�W�i�ܤFeblasakimab���s��ƼƾڡC�P Shawn Kwatra �դh�M Madan Kwatra �դh���b�i��X�@���Ĥ@��ƾ���ܡAAD �w�ֽ̥��˥����Τj�ӭM�M�ݻĩʲɲӭM�� IL-13R�\1 ���F�W�[�A�q�ӥ[�j�F IL-13R�\1 �b AD �����֤ߧ@�ΡC�b�H�����g���ҫ����A�̥��԰��� ��ۭ��C�F�Ѥ��P�� IL-4 �M IL-13 ��o�~�|�ް_�����g����o�ӷP�ʡA�åB�ٽT�w�F IL-13R�\1 �H���Ǿɦb���� AD ���~�����g�����ĩʩM�ӷP�ʤ����s�@�ΡC
�k�|�F (ASLAN003)

�ֽ��ۨ��K�̩ʯe�f���{�ɶ}�o�p�����b�̫�V�w�A�w�p 2023 �~�W�b�~�}�l�i�� 2 ������C
�w�p�Y�N��Ӫ����{�O

�� 2022 �~���A�Ĥ@��w�̰ѥ[�F TREK-DX ����C
��Xeblasakimab�@�ξ���W�S�@�Ϊ��s��ƼƾڱN�� 2023 �~�줽�G�C
eblasakimab 2b �� TREK-AD ���窺�@�u�ƾڹw�p�N�� 2023 �~�ĤG�u�׵o���C

ASLAN Q3�]����资�T��s�C
finance.yahoo.com/news/aslan-pharmaceuticals-reports-third-quarter-110000300.html

�� 2022 �~ 9 �� 30 ��A���q�H 6,890 �U�������{���B�{���������M�u�����������d���g�窬�p�F �w�p�� 2023 �~�����]�D

��s eblasakimab �b dupilumab ������O���s TREK-DX �{�ɭp���g���F�S���ʥ֪� (AD) �w�̡A����b 2022 �~���e�۶ҲĤ@��w��

eblasakimab �b���g�ͪ��v���L�����צܭ��� AD �w�̤��� 2b �� TREK-AD ���祿�b�i�椤�A�w�p�N�b 2023 �~�ĤG�u�ײ��ͤ@�u�ƾڡC

Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023

New TREK-DX clinical program studying eblasakimab��s potential in dupilumab experienced atopic dermatitis (AD) patients on track to enroll first patient by the end of 2022

The Phase 2b TREK-AD trial for eblasakimab in biologic naïve moderate-to-severe AD patients is on track and anticipated to generate topline data in Q2 2023

���j�A

�]�G���N�A
随缘���ܡA
����随缘�C

11�뤤���A����Q3�]���A���p�|�ť�2b ���ק����C

�����~2�뤤��-3��W���Ѫ��C

�ѩR�j

�p��2���}���}�e�C�A�S�X�j�q�A�۩��i��ܡA
�Pı���K�y�F�A�n�����Ȥ@��

�Q�F�ѱz���ݪk

���v�̧C��0.3555�֨�F
�q�`���ѹL�����q�A�������o�_��
�����o�_�Ӫ����q�A�q�`�n�B��F
�[�o�I�ȷ��ܶ���I�ѻ��w�g�z�ը칳�Q���@��
�ڤw�g�����ݸѪ�������i��F
�N��۷��ֳz�A�[�[�Ӫ��W�ݤ@�U���j�A

���] ��� Lebrikizumab 2b ����

clinicaltrials.gov/ct2/show/results/NCT03443024

1.IGA0,1
��Ӳ�=15.3%

4�g�@�w 125mg =22.6% p=0.1917(p��>0�P05�^
4�g�@�w 250mg=33.7% p=0.0392(�T������18��52�g�����v�����@�A�õL1��16�g�v���]�p�^
2�g�@�w 250mg=44.6% p=0.0023

2�PEASI75
��Ӳ�=24.3%

4�g�@�w 125mg =43.3% p=0.0610(p��>0�P05�^
4�g�@�w 250mg=56.1% p=0.002)�T������18��52�g�����v�����@�A�õL1��16�g�v���]�p�^
2�g�@�w 250mg=60.2% p=0.0005

280�H�@4�աA58�Ӥ��ߡA����4.82�H������

�H�W�]�p�A�Y�Ϧ��C�ӤH���C�G�g��ơA�p�G�L�Ѫ��A�ݤ��X�C�ժ����ġC

ASLAN004 2b �A��h�զ@5�աA���]295�H��65���ߡ�4�P5�H/����⋯⋯
���g�Ѫ���ݤ��X�A�U�ժ��u�H�C

�Ѫ���ા�x�A�U��p�ȡC

ir.aslanpharma.com/static-files/60a95013-835e-4341-9b3b-270ce73b9b1d

2022/Q2 ASLN �]���A�p�W

�b��3200�U����
�l�q-1300�d�U�����@Q2
�{��7800�U����

��2022/Q4. �b�Ȧ���600�U����
�{������5200�U�����C�]�C�u�l��1300�U�����^

finance.yahoo.com/quote/ASLN/?p=ASLN

ASLN ���L����3080�U�����C
�@�@�@�@

ASLN���q�ѻ��A�ثe�H�]�P��Ӫ����ȳ̷ǽT�C

2b �Ѫ��ƾڡA�Y�p�w���]�p 1bmITT EASI 69%/IGA 44%),�ؼл�7�����A�U���]�P��5�D6�������ѡC

�`ı�o�ثe�ѷ઺�ѻ��A�����O�Ѫ������G�n�W�V��������Lebrikizumab���˺A�A�Y�ϸѪ����W5���A�]�u��2.25�A�u�O�����Ӥw�A���I�OCEO�n�V�O�@�I�A�h�����ѻ��A���M������c�Ӹg��]�����C���j�A

�H�U�ӤH�[��C

����p���s�ĪѪ��ѻ������ȱ`�b�����ĵ��ɱ���Ѳ��b�ȡC

���o�ĵ���3�Ӥ몺���Ȭ��԰���C�����{�i�y�p�P���Bx3���C

�Q���ʻ���=�C�~��~�b�Ȫ���{��

�]�pLebrikizumab 2019�~�������ڬw�ϾP��A�W����5�~�̰��P��15�������A�C��~�Q�q��{11�������^�A�̫�11�������Q���ʡC

���ʤ��q�i�b�b�Ȫ���¦�W��T���H�W�ѻ����S�C

���q�D�ޥD�n���J�A�Ҿa�Ѳ������A���ꤽ�q���ѧQ�ҵ|���A�ҥH�h������ҶR���q�w�êѡC

CNTB���qCBP201 AD 2b �Ѫ���(�q2021/07/28)�A
�ѻ��b����23-28�����A11��19�餽���Ѫ��ƾڡA�����4�����h�C

DERM���q Lebrikizumab AD 2b �Ѫ�/����(2019/02/07)�����C

�ѻ��b�C��6���h�����A�Ѫ�����j��约�@����12�������k�C

2019�~10��}�l�T��AD�{�ɡA�ѻ��^�쩳�I6�������k�C

2019�~12�� 18�����h/�ѡA�Q§�Ӥ��q�ť����ʡC

�ѩR�j
�P�±z���^�_

�i��O�x�Ѥ��u������Y��
�`�{���Ѳ��H���ޱ����]�����j

�ѻ����շ|���ϬM���q���ӡA�]�����H�w�����D

�Ҧ��{��004 2b�ƾڥi�ण��

�z�������a���q�ѻ��̧C��6.6��
�q�������C��1���A���U���M��

���j�A

www.clinicaltrials.gov/ct2/show/NCT04444752?term=NCT04444752&draw=2&rank=1

CBP 201 AD, 2b
2021/7/28 �D�n资��(16�g������)�C

�L���ѻ��A���s�ʲ{�H�C

finance.yahoo.com/quote/CNTB/

2021/08/10 �̰��ԤW28�����C

(2021/7/28 �i��w�Ѫ��H�H�H)
2021/11/19 ���G�ƾ� �����4���h�����C

��Ĺ�b�Ѫ��餧��C

004 2b����
�q8��26���A

�Y�L����i�ק�s���

���j�A

DERM (Lebrikizumab )

2019/02/07 AD2b �Ѫ�
2019/02/12 �ڬw�ϱ��v

DERM �ѻ����աA�p�U

www.netcials.com/stock-price-chart-history-nasdaq/DERM-Dermira-Inc/

�ѩR�j

�̪񦳤���Q��

����ѻ������򨫧C
�@�L��^��H
�O�_�i��O004 2b�ƾڤw���H�����D

�ץ�-1
ASLAN004
1b mITT�]8�g�v���^ vs 2b ITT����� �]16�g�v���^//��Ӳմ���ȡ]16�g�^//(������Ӳի�Pk�^

EASI75 =69% vs 73%// ��Ӳ�24%//(�t�� 45% vs 49%)---�ץ�-1(���_�v3/16,�i��U�ר�1/16.��ɥi��A�Ԥ�EAS75 ��80%�H�W���v���p)

IGA0�A1 =44% vs 57%//��Ӳ�15%//�]�t�� 29% vs 42%)

�@�@�@�@�@�g16�g�v����IGA0,1 �|�A�����A�pLebrikizumab 2b/ph3 EASI75 �MIGA0,1�t�Z16%�]16�g�^

Lebrikizumab 2b//ph3 �P�˼v�TIL13a1,���ħ󦳰Ѧһ��ȡA�u�OASLAN004 �IJv��֡C
�@�@�@�@16�g����Ӳ����İѦ�Lebrikizumab 2b��ơA���p��缐EASI�b25.5~27.5���ǡC

�ȷ�d����l�ѥ�500�A000�d��//ADR100�A000�d�ѡC

�Y���԰��ѻ���18.5�����H�W�A���p�����Ҩ�3���{��4������������C

�ݦA�l�}�ѪF�|�X�W�ꥻ�B�C���p�ܤּW�[��50%�A�W�[��ADR150�A000�d��

75�A000�d��x7��x80%x97%=��4�������]����DERM AD2b�Ѫ��᪺����s�q�^
�@�@�@�@

�t�@�覡�N�O�԰��ѻ���18.4�����H�W

18.4x80%X97%=14.28����

4������/14.28=28,000�d��ADR�]���ΦA�X�R�ѥ��^

���ȩԤɦ�15~18.5�������H�W�A�p���Q���ʻ��A�@��40��������n�͡C

���q�n�[�o��ILebrikizumab AD �̰��P��w�O�u����45�������C


���q���X��1b�����Z��ƨ��H�������v�e����ưѦҡG
aslanpharma.com/news/?cat=publications

�p���v�ͧP�A�N�̾ڸѪ��ƾڨөw���ȡC
��ץi�����]
A�D���ĦP1b mITT �ɪ���Է���ȡH�]��b�y�p�P����{����{�ȡ^
B�B���İ��� 1b mITT�ɪ��������ȡH�]���^

���Ѫ��A�L�ջ��ȡC

ƿ�@�@�@�@

ASLAN004
1b mITT�]8�g�v���^ vs 2b ITT����� �]16�g�v���^//��Ӳմ���ȡ]16�g�^//(������Ӳի�Pk�^

EASI75 =69% vs 73%// ��Ӳ�24%//(�t�� 45% vs 59%)

IGA0�A1 =44% vs 57%//��Ӳ�15%//�]�t�� 29% vs 42%)

�@�@�@�@�@�g16�g�v����IGA0,1 �|�A�����A�pLebrikizumab 2b/ph3 EASI75 �MIGA0,1�t�Z16%�]16�g�^

Lebrikizumab 2b//ph3 �P�˼v�TIL13a1,���ħ󦳰Ѧһ��ȡA�u�OASLAN004 �IJv��֡C
�@�@�@�@16�g����Ӳ����İѦ�Lebrikizumab 2b��ơA���p��缐EASI�b25.5~27.5���ǡC

���]
�̾�DERM ���qLebrikizumab AD 2b,2019/02/07�Ѫ�,02/12�ڬw�ϰӷ~���v�O���v.

ASLAN004

2022�~10��15��ASLAN004 2��, �w�����̫�@�H�B���Ĥ@�w.
2023�~2��15��Ѫ�
2023�~2��16��Ҹ�(�p��/�]�P)3~5������,�dzư��T��.
2023�~2��22��ڬw�ϰӷ~���v�O���v.

�{�b���q���Ӧb�����?
���ӫܦ�!!!

Pk

1.Lebrikizumab 2b
clinicaltrials.gov/ct2/show/results/NCT03443024

����PK(��uEASI25.5)
����� vs ���组

EASI75 61% vs 24%(�t��37%)
IGA0,1 45% vs 15%(�t��30%)

2.Lebrikizumab ph3

16�g

����PK(��uEASI???)
����� vs ���组
(1)AD1
clinicaltrials.gov/ct2/show/results/NCT04146363

EASI75 59% vs 16%(�t��43%)�K�K�K�K�l�[��52�g����组����47%
IGA0,1 43% vs 13%(�t��30%)�K�K�K�K�l�[��52�g����组47%~45%//����46%

(2)AD2
clinicaltrials.gov/ct2/show/results/NCT04178967

EASI75 51% vs 18%(�t��33%)�K�K�K�K�l�[��52�g����组����41%
IGA0,1 33% vs 10%(�t��22%)�K�K�K�K�l�[��52�g����� 41%~33%//����37%

(3)Lebrikizumab�QTCS
Lebrikizumab �QTCS��16�g �T���A�������组
@%
IGA. 41-22=19
EASI75 70-42=28

3.ASLAN004 2b �����
��u���]EASI25.5(�PLeb. 2b)
����PK
����组vs ��Ӳ�
EASI75 73% vs 24%(�t��49%)
IGA0,1 57% vs 15%(�t��42%)

4.Dupilumab ph3
www.nejm.org/doi/full/10.1

16�g
��uEASI32.5
(1)SOLO1
EASI75 51%vs 15%(�t��36%)
IGA0,1 38%vs 10%(�t��28%)
(2)SOLO2
EASI75 44%vs 12%(�t��32%)
IGA0,1 36%vs 8%(�t��28%)

(3)Dupilumab +TCS
16�gvs 52�g
clinicaltrials.gov/ct2/show/results/NCT02260986

A.EASI75
QW//Q2W//��Ӳ�--%

16�g63.9//68.9//23.2
52�g64.1//65.2//21.6

B.IGA0,1
QW//Q2W//��Ӳ�--%

16�g39.2//38.7//14.2
52�g40.0//36.0//12.5-----------(2017/10 ���G)

5�BLebrikizumab �y�p�P��预����������v45-150�������C
§�Ӥ��q�{���i�� ��-����AD�Ĥ@�u�Ī��C
(�ӤH�{��Lebrikizumab 45�����������|//�Y�LASLSN004�W��)
Dupilumab ��REGN ���q���y�p�P��130���ڤ��C

���j�A

�H�U�P�ݭӤH����A

ASLAN004 2b �{��
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3

���]65�Ӥ��ߦb2022/08/30�}�S���̫�
ASLAN004 2b �{�ɡA�w���Ѫ�����G2023/02/15
�w���̫�@�짹���Ĥ@�w�`�g����G2022/1015

⋯⋯⋯�̾�Lebrikizumab 2b�{�ɪ��ɵ{�g��C

⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯
�|���G�ѩR10141925 �o���ɶ�:2022/10/7 �W�� 08:44:19�� 5683 �g�^��
clinicaltrials.gov/ct2/show/NCT03443024

Lebrikizumab 2b �{�ɰO��

2018/8/23 �̫�۶Ҥ���资�Ƨ�s
2018/10/6�]�����̫�@��w�̥��Ĥ@针����^
2018/11/06 ����۶Ҹ�Ƨ�s
2019/02/07 �Ѫ�

���j�A
���ק������ݨ̾�Lebrikizumab 2b�{�ɱ����A

���]8��30��65�Ӥ��߬��̫᦬�פ��߶}�]�A�g45�Ѫ��z�˩Ұ���]�PLebrikizumab)

�@���̤��q�������ǡC

�ѩR�j

ASLAN004 2b�w�����̫�@�즬�סA�O�_���@���״X�H����T��

�̾�Lebrikizumab 2b ���{�g��C
��

ASLAN004 2b
2023�~2��15��Ѫ��C
�̫�@��w���ק����Ĥ@�w�C�b2022�~10��15��

www.aad.org/member/meetings-education/am23/faculty/abstracts

AAD 2023

�̷s��s�פ�`�� �̫᦬���G2023/01/13

�аݦU��j�j:
���Y004��112�~2�뤤�Ѫ����V�A�аݨӱo�ΰѥ[���~�׬���ֽ��Ƿ|(�q���)��?
(��(111)�~����ֽ��Ƿ|�O�b3��25���|��).
§�Ӥ��q�b9��8��o��
Lebrikizumb
�T��52�g�{�ɳ��i

���q�۫H
����Lebrikizumab �Y�Q�֭�W���A
�i�Q�Ω�v����-����AD���Ĥ@�u�Ī��C

���ڭ̦b�S���ʥ֪��{�ɸ��綵�ؤ���o��í���B�㦳�{�ɷN�q�����G�A�ڭ̬۫H�A�p�G��o���Alebrikizumab �i�ন���ֽ�����ͤΨ�\�h�w���ϤH�I�z�g�������צܭ��ׯe�f�w�̪��@�u�v���Ī��ôM�D�s���v����ܡA�ç���w�������W�c�����ġA��§�Ӥ��q���y�K�̾Ƕ}�o�M��ǨưȰ��`�� Lotus Mallbris ��dzդh��
Based on the robust and clinically meaningful results from our clinical trial program in atopic dermatitis, we believe lebrikizumab, if approved, could become a first-line treatment for dermatologists and many of their patients with moderate-to-severe disease who suffer from debilitating symptoms and seek new treatment options and prefer less frequent dosing, said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly.

finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html

�̾�Lebrikizumab AD���O�u�P�����45�������C

004 2b �Ѫ��p预��
EASI 75 73% vs Leb. 2b 61% vs ���组24%

IGA0,1 57% vs Leb. 2b 45% vs ���组15%

���] ��uEASI 26-EASI 28

�h��bAD �QASLAN004 ���ʪ��B 约��2020�~Leb.�Q�֪��B 11������x3��=33�������_���C(���ɦ�15���������y�p�P��K�K����欧�w区)

��L�A���g=33/0.55-33=27������(2������)
���ӹ���٦�13.5�������C

33+13.5=46.5������

���p�Q���ʻ��b45-50�����������C

���]1000,000�d��ADR �ѥ�

�C��45-50���������C

�W�L�]���N�~�C

�H�W�ӤH����C

ASLAN004 �����u��Lebrikizumab ,�]MOA���Y�A���ĵL�kí�w�A�ɦn���a�C

Lebrikizumab �x�b���ݡ�COPD �T���{�ɥ��ѡA�x�����{�ɸ���C

Lebrikizumab �ȦbAD���P��N�Q����45�X150���������y�p�P��C
�@�@�@�@�@

1�ALebrikizumab �T���{��
vs��Ӳ�

AD1.
IGA. 43% vs 13%������Ӳ� �t��30%�^
EASI75 59% vs 16%�]������Ӳծt��43%�^

AD2
IGA 33%. Vs 11%(�t��22%�^
EASI75 51% vs 18%(�t��33%�^
�@�@�@�@�@

2�ADupilumab �T��
Solo1
IGA 38% vs 10%�]�t��28%�^
EASI 75 51% vs 15%�]�t��36%�^
Solo2
IGA 36% vs 8%(�t��28%�^
EASI75 44% vs 12%(�t��32%�^
�@�@�@�@
3�AASLAN004 2b �ؼ�����

IGA 53% vs 15%(�t��38%�^
EASI75 73% vs 24%(�t��49%�^


Lebrikizumab �y�p�P��45�������@�@�@������R�vEdmund Ingham��

�̰��w����150�������C

2022/09/28 �峹�p�U

I am more optimistic on sales of 2 newcomers however in Lebrikizumab and Mirikizumab.

Lebrikizumab has been compared to Sanofi��s Dupixent, itself forecast to achieve peak sales of ~$15bn by some optimistic analysts, and has even outperformed Dupixent in some studies, so perhaps I am being too conservative forecasting peak sales of just $4.5bn.

Lebrikizumab �M Mirikizumab �� 2 �W�s�Ī��P��󬰼��[�C

Lebrikizumab �P�ɿյ᪺ Dupixent �i��F����A�@�Ǽ��[�����R�v�w�p��P���B�p�ȱN�F��� 150 �������A�b�@�Ǭ�s���ƦܶW�L�F Dupixent�A�ҥH�]�\�ڹL��O�u�a�w���p�ȾP���B�Ȭ� 45 �������C

Eli Lilly: Valuation Feels Impossibly High - Don��t Board This Hype Train

Sep. 28, 2022 12:26 PM ETEli Lilly and Company (LLY)9 Comments
1 Like

Edmund Ingham

seekingalpha.com/article/4543610-eli-lilly-valuation-feels-high-dont-board-the-hype-train

�MDupilumab ���i��M�Q���D�A���b2037�~�e����W���C
����ӽдX�~��W�����i��A

����2�� �D�n����IGA 0,1 ��30.3%���C.

�Q��CNTB�ѻ��S�C��1�����A��0.95�����A���b�̭p���b���ꥫ���Ҷ�3���������T��AD�{�ɡC

CNTB 2023/10/04 ���G CBP201 ����2 �����@����AD�{�ɸѪ����i
October 4, 2022

�@�@�@

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
finance.yahoo.com/news/correcting-replacing-connect-biopharma-reports-125600879.html

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD

Safety and tolerability results for CBP-201 consistent with targeting the IL-4R�\ pathway

Data support advancing the regulatory discussions with the CDE for submitting an NDA in China

����� vs. ��Ӳ�
�D�n����IGA0�A1 30.3% vs 7.5%(������Ӳի�22.8%//Dupilumab�T����28%�]38%vs 10%�^�^
���n����
EASI75 62.9% vs 23.4%�]������Ӳի� 39.5%//dupilumab �T����36%�]51%-15%) )
EASI50 83.1%vs 43.1%
EASI90 35.8% vs 6.3%

The primary endpoint of IGA of 0 or 1 (��clear�� or ��almost clear��) with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001).

CBP-201 also met key secondary endpoints, including 83.1%, 62.9% and 35.8% of patients achieving a 50%, 75%, 90% reduction in the Eczema Area and Severity Index score (EASI-50, EASI-75, EASI-90) from baseline compared to 41.1%, 23.4% and 6.3% for the placebo group (p < 0.001), respectively. Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo (p < 0.001).

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
clinicaltrials.gov/ct2/show/NCT05017480?term=Cbp201&draw=2&rank=2

Tang Capital Management LLC �̪�ť����� ASLAN Pharmaceuticals Limited�]�Ǵ��F�J�Ѳ��N�X�GASLN�^���s�ѥ��C���c���̳q�L�ʶR227�U�ѡA�N��b�����O�����q�����v�W�[69.04%��555�U�ѡC�o���s���{�b�Ϩ���Ѥ�ҹF�� 7.97%�A�ثe���Ȭ� 344 �U�����C���~�AMillennium Management LLC �W�� 43949.0 �Ѧ� 161 �U�ѡCRenaissance Technologies LLC �w�N���Y�o�W�[ 574.07% �� 41 �U�ѡA�� 48 �U�ѡC�Ʊ��٬O�|�����V�����ƾڡA�o�˹�ѷ�ͤ���n~~ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c

10��7��̷s�����q²��

clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3

ASLAN004 2b �{�ɡA�w���Ѫ�����G2023/02/15

⋯⋯⋯�̾�Lebrikizumab 2b�{�ɪ��ɵ{�g��C
�A��11�뤤���|�ť��A�w�����̫�@��۶ҡA�Ӱ���۶ҡC

�p�����W���A���Ӥ��|���������i�C

⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯
�|���G�ѩR10141925 �o���ɶ�:2022/10/7 �W�� 08:44:19�� 5683 �g�^��
clinicaltrials.gov/ct2/show/NCT03443024

Lebrikizumab 2b �{�ɰO��

2018/8/23 �̫�۶Ҥ���资�Ƨ�s
2018/11/06 ����۶�
2019/02/07 �Ѫ�

www.nature.com/articles/s41573-021-00266-6.pdf
���~�즳�H��z���峹 �̭�������ASLN004������
ASLAN004 is a fully humanized antibody directed against IL-13R�\1, thereby blocking the binding of IL-4 and IL-13 on the type II receptor (IL-4R�\/IL-13R�\1). Owing to the more selective binding compared with dupilumab, ASLAN004 may provide the option of a low-dose regimen and a better safety profile. An interim data analysis from a phase Ib study showed that the com- pound is well tolerated and provided promising efficacy data, with 67% of the patients achieving EASI75 versus 0% in the placebo groupclinicaltrials.gov/ct2/show/NCT03443024

Lebrikizumab 2b �{�ɰO��

2018/8/23 �̫�۶Ҥ���资�Ƨ�s
2018/11/06 ����۶�
2019/02/07 �Ѫ�

600mg组16�H�K�KmITT,���_3�H
(65%��16-27%��2)/14=70%�P�P�P�P��断�v�վ㬰1�H�A1/14=7.1%�K �K�K�K��8�g���������ġC

Pk Dupilumab ����8�g�q�� ��65%

70%/65%=108%�K�K�K�KASLAN004�b��8�g�������Ħ�8%�u��dupikumab���ͶաC

1�B
www.nejm.org/doi/full/10.1056/nejmoa1610020

�ϤG�C
Dupilumab 2�ӤT���{�� EASI �U���U�g�Ͷժ��C
...16�g

2.ASLAN004 1b mITT
�U�gEASI�U���Ͷժ��C
�K�K8�g�A
�p�Ϥ@�C
ASLN ���Z����
aslanpharma.com/news/?cat=publications

EADV(2022) �ĤG�Ӵ��Z
Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded,
placebo-controlled, Phase 1 study

3.PK
ASLAN004 EASI �U���T��/�t�פ�Dupilumab �T���u�C

�U��EASI50 ASLAN004 �b�ĤT�g�F��ADupilumab �b�ĥ|�g�~��F�C
�U����EASI60 :ASLAN004�b�ĥ|�g�ADupilumab �b��5�g
�K�KDupilumab �T����断�v7�P5%�C(��uEASI32.5)
A.��uEASI25.5/�CTRAC �A�������TEASI 77%
B.��uEASI31/��TRAC �A�������TEASI 67%
C.��uEASI42/��TRAC,�������TEASI66%
�`������u32.5�A�������TEASI 70%
....�H�W�U组�H�Ƭ۪�C
�K�KASLAN004 1b mITT (��uEASI 31.2)
��断�v3/16=18.8%�K�K600mg

�����]�I���q�b���浹�����Ҩ����e���|���̷sForm 13F��󤤺١A�Ӥ��q�b�ĤG�u�ױN��b�������s�Ħ������q(�Ǵ��F�J�N�X�GASLN-GET����)�����ܤW�դF7.3%�C�Ӿ��c���̦b���u���B�~�ʶR�F2.4�U�ѫ�A����35.3�U�ѸӤ��q�Ѳ��C�I�̪ܳ�@�өu�ץ��A�����]�I���q�֦��������s�Ĥ��q��0.51%���ѥ��A����17.5�U�����C
004 1b mITT
TRAC/IgE ��20�g����ƦU�g�ͶչϡC
�b���qEADV2022 ���Z�C

TRAC���Цb��3�g�N�X�G����̧C�C

IgE �b��12�g~14�g����̧C�C

(��7�g�̫�@�w)
600mg 16��AmITT����3�줤断�w�̡C
�Y����������v�|�̰��C

�ͪ����Цb��8-11�g��维���b�C�ɡC

���q��2b�{�ɪ����w�]�p�ܤj�����Ӧۥ����i�C

�ٰѦҡAPK�A�����A��Է�v���C

���N�ODupilumab

ASLN �u�����]赢8%�C

�n�n��sDupilumab���ASLAN004 1b mITT.
����U���H�ߡC

�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K

Dupilumab �U���{�ɼƾڡC

1. Dupilumab �����|�� AD �{�� 4�g/12�g ,
2014/07/10

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

www.nejm.org/doi/10.1056/NEJMoa1314768

2. Dupilumab 2a/2b �{�� ,2018/SEP

journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx

3.Dupilumab AD 2�ӤT���{��, 300mg/�C�g�@�w/300mg/�C�G�g�@�w
2016/12/15

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
www.nejm.org/doi/full/10.1056/nejmoa1610020

ASLAN004 2b�����w�{�ɳ]�p

0,1,2 �U�@�w�A��21�Ѯɶ��A

200mg/400mg/600mg(��lb mITT),�������ĥi��EASI50,

���]�̫���������FEASI75 ,

3�w�N�i�F66%����终���G�C(50%/75%)

��L���|�g�@�w�ݳy�ƤF�A�p�G�F�дN�h�Ƚu40%�����n�סC(�۹��dupilumab ,�i�F54%.)

2�g�@�w4/6/8/12/14�g�U���@针300mg/400mg,
�ؼбNEASI75��IGA0,1 �Ԩ�73% / 57%,���\�v�������C

������dupilumab,赢8%�_�h�u�७�������C

�K�K�K�K�K�K�K�K�K�K�K�K�K�K
Lebrikizumab 2b 4�g�@针�bIGA,0,1���F��ۮt���A�ҥH�T���{�ɩ�b18-52�g���������{�ɡC

Time is our best friend !
�ɶ��O�ڭ̳̦n���B�͡I���j�A

�ӤH�P�_�C

�ثeDupilumab �ڬw�P�����12%�A
lebrikizumab 2b 58���ߥ��b����A�ڬw���s�C

�Y�n�}�ڬw��������9��N�n���i�C

�H�W�ӤH�q������]�C

�Ш̤��q���i���D�C

�Y�u���u�}65�ӡA�A��11�뤤���U�����Ӥ��i�����̫�@�ӡC

�ѩR�j

���פ��߬O�_�Ȱ��d�b65�B

���A�s�W�A���Ѥ��q�����䥼�Ӿާ@���e�A
�Ϊ̬O�A���߰ݹL���q
�P��

clinicaltrials.gov/ct2/show/NCT05158023
004 2b clients.

���ʤ��: �٬O���b8��30 ��.

�ӤH�q65 �Ӥ��߬��̫᪺�۶Ҥ��߼�.
�ڬw�w�̤T���A�Ӱ��N��F.

�t�j�A

�O���C

�аݤѩR�j�H�U��p�ɤ���h�z�Ҵ��o�O�P�@��ƶ� ? �Y�O�A�N�O�z�]�{�P�~���������ƾڡA�u�O���V�P�_��?

�|���G�ѩR10141925 �o���ɶ�:2022/9/30 �W�� 09:52:19�� 5668 �g�^��
�p�G65�Ӥ��߬���终�ƶq�C

���|���������i�C

���~3���Ѫ�295�H�����v���C

�Y须100�Ӥ��ߩ۶ҡA�������R�N�i�ର���n�C

�|���G�ѩR10141925 �o���ɶ�:2022/9/30 �W�� 11:22:32�� 5670 �g�^��
�رi�j�A
�u�}65�Ӥ��ߡA12�������Ѫ�+�p�ҡA�O�۹�X�z�B�w������סC

�]�O2023�~3���C

�H�W�ӤH�q���C

�رi�j�A
�u�}65�Ӥ��ߡA12�������Ѫ�+�p�ҡA�O�۹�X�z�B�w������סC�ѻ��w�g���O���ȷ�d�U�������D�F�A�N��112�~3��27��ѻ��٧C��1�����A
���q�٬O��Q�δ�굥��L�覡(���q�b���i��������)���ȷ�d�@���d�b�����F�J�ꥻ�����C

���פ��ߥثe��65�B�A�O�_�A�W�[?
�O�u�@�I�A�ڭ��[���10�멳�A���ɭY�L���פ��߼W�[(�Y10�멳�e�A��s�A���~�֩w�Ӥ��θѪ�)�A
�N�T�w�O65�B���פ��ߵL�~�F�C

���]65�B���פ��߬O�̲׵��G
�b111�~5��6��ɡA���q���ɴN�w���i����36�Ӧ��פ���(���v�W�L�@�b����H��)�A
�F���i�������i���v�H���̧C���e
5��6��+2�Ӥ�۶�+4�Ӥ�v��+1�Ӥ��ƾ�z=111�~12��6���i�H���i�������i(�H�K�i��p��)�C

111�~11��6��᤽�q��W�w�g���@�b���v�H�����Ѫ��ƾڡA�p�һ��O�_�}�l�s�ʡK�K
���q��W�ͧP�w�X(���Ѫ��ƾ�)�A�w�g���F��112�~4��Ѫ���ñ�p�ڬw�ϦX�����v���a�O���C
112�~4��Ѫ���A���v���a�O���������W���C

�p�G65�Ӥ��߬���终�ƶq�C

���|���������i�C

���~3���Ѫ�295�H�����v���C

�Y须100�Ӥ��ߩ۶ҡA�������R�N�i�ର���n�C

�]�O2023�~3���C

�H�W�ӤH�q���C

65*5=325 �D�`�������۶ҹw���H�ơA���ֻ{�u�J�Ӧ��סA�����������V�ƾڡA�������{�P�ѷ઺�g���V�C�[�o!�ѷ�clinicaltrials.gov/ct2/show/NCT03443024

Lebrikizumab 2b AD �{��

4组/280�H�C�}58�Ӧ��פ��ߡA���b����C

2019�~2���Ѫ��A7�ѫ�ñ�p欧区���v�X约�C

���B�[�}36��(30+6)
�D�w6/�L��8/纽����1/�s�[�Y4,�p�p19�Ӥ���

�X�p65��004 2b�۶Ҥ��ߡC

欧�w�������۶Ҿ��v�D�`�j�C
65�Ӥ��ߨ����w�I

www.clinicaltrials.gov/ct2/show/NCT05158023

004 ��2b �{�ɡA�w�}��65�Ӧ��פ��ߡC

8��30��ܤ��������ʡC

欧���M����FDA����ñ�p�{�ɹ���资�Ƥ��۩ӻ{���X约�C

�ҥH�b������o�ĵ����{��资�i�������h�ӽ��ĵ��A�p���Ϊ��R���f�ĵ��C
�b欧�����o�ĵ����{��资�ƥ�P�i�������h�ӽЬ����įg�A�p�ĵ��Ī�PV�ĵ��C

8��30��}�ߤ�����
+2�Ӥ�۶�+4�Ӥ�v���C
预�p2023�~2�멳~3���i�Ѫ��C

ASLAN004 2b����ȡG

004/2b ��断�v
�Plb�b3/16=18%

EASI75:(11+5)/22=73%�K�K��lbmITT+���g�վ�预��5/6

IGA0,1=EASI75 73%-16%
=57%

(��Lebrikizumab 2b 2�۫��Юt���Ҧ�)

�G2b ����Ȧ�
����组�@���组(�PLeb. 2b���组)
EASI75 73% - 24%=49%
IGA0,1 57% -15% =42%

�H�W�i预������3���γQ���ʻ��Ȫ��ѦҡC

Ph3 ����uEASI�|�Ԥɦ�32-33.
���组���Ħ۵M���C�C

Ph3.�����_�v�b����ճq�`��7%-8%
���b2b�ɡA�q�`����20%.

�]��2b�Mph3(�T��)�A�������组���D�n��������
IGA0,1��EASI75 �|�۪�C

Lebrikizumab �]M0A����A�G�ӤT���{�ɮt��30%���ġC

Dupilumab 2�ӤT���AIGA0,1�������组��P��28%

ASLAN004 ���ӷ|�PDupilumab ,3��2���{�����ĸ��@�P�ʡC

Lebrikizumab 2b vs ph3

1.EASI75
����组-���组

2b: 61% -24%=37%

Ph3:
Ad1 ,59%-16%=43%
Ad2,51%-18%=33%

2.IGA0,1
2b : 45%-15%=30%
Ph3:
Ad1 ,43%-13%=30%
Ad2 ,33%-11%=22%

Immu ���q���NImmu132 ADC�A mTNBC �T�u�A��L�A���g�C
���y�P���v�b���oBTD�A
�ΥH1/2���{��资�ƥӽ��ĵ��C

�H20���������v给����詤���t�@�a���q�C

�ѻ��q3-4����(2015�~��BTD)
2016�~���v�A�K�K16�����C

��Ӥj�ѪF���P�N�A�}��CEO�A

�ۦ�W资�A�����T���A2020�~����o��证�C

2020�~��200�������Q���ʡA�ѻ�90�������k�C

Tang 资���޲z�w���o5555�d�ѡA��8%�A

���靈��O�v�T���q�M���C

www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/#!po=33.4821

Lebrikizumab 2b �{��资�Ʀp�W�C

���组 ��uEASI28.7
����组 ��uEASI25.5

EASI75 24%
IGA 0,1 15%

�٬O�i�ޥΡC

�]��004/2b ���ؼ����ġA维�����e
EASI 75 =73% vs 24%,�������组��49%
IGA0,1 =57% vs 15%,�������组��42%
�K�K�K�K

Dupilumab 3��SOLO1/SOLO2�A�������组
EASI75 36%(51%-15%=36%)/32%(44%-12%=32%)
IGA0,1=28%(38%-10%=28%)/28%(36%-8%=28%)

Pk(�������组)
ASLAN004 2b �����vs Dupilumab 3������
EASI75 49%/34%=144%
IGA0,1 42%/28%=150%

ASLAN004 �u��Dupilumab 3��SOLO1/SOLO2 ���ͶաC

�H���ּw����C

�߬�Ǽƾگ�H���C

CAPITAL MANAGEMENT �A����R�i�J�DASLN�A

�O�i�઺�C

�ѻ���20�����A�N�u�u�j�Ȥ@�i�C

............�K�K�K�K�K�K�K�K�K�K

ASLAN004 2b�ؼ����ĭץ��C(���组)

��u EASI (31.2��16+19��6)/22=27.9.�K�K1b/aslan004 ����

�K�K�K�K�K�K�K�K�K�K
Leb. 2b, EASI75= 24%....���组,��u EASI25.5
Leb. P3 EASI75=16%......���组�A��u��EASI31

(24%-16%)/(31-25.5)=1.46

内���k
ASLAN004
2b EASI 27.9 ���组EASI75��20%

EASI27.9=24%-2.4%��1.6=20%

ASLAN004(��uEASI28)
�ؼ�

EASI 75 =73% vs 20%//�t�� 53%

IGA0,1=57% vs 12%//�t�� 45%

�ѷ�n�ǥx�W���İ�X���g���O�A�Ѫ������ٯ�N�ѻ����b60���H�W�A�N����ɶ��h���ߺ�������; �ݨ�TANG CAPITAL MANAGEMENT�ܦ�����,���Ѥ]��,�o�ʩ_ŧ�ӷ���ɶ��h�]�O����~�ѩ�Dupilumab +TCS �񥼥[TCS��Dupilumab,
�bEASI75�W�[45%�����ġC
�G须��SOLO1/SOL2 q2w �A
16�g���� ESSI75 47.5%����¦�C�K�K�K�K�K�KA
IGA0,1 ����37%�K�K16�g
IGA0,1 ����35%�K�K52�g(��Dupilumab+TCS 52/16�g��2.5%)�K�K�K�KB

B/A=74%.

�G60�g�jpK�Ҧ��G�A�p�U�C

Dupilumab 74% vs Leb. 75% vs Tra.
50%
�K�K�K�K�K�K�K�K�K�K�K�K�K�K
60�g维���v�C(�T��AD�{������)�jPK

1.IGA0,1

Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50%

60�g维���v�C(�T��AD�{������)�jPK

1.IGA0,1

Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50%

2.EASI 75 60�g维���v

Dupilumab+TCS 95% vs Leb. 80% vs Tra. 55%

���G
IGA0,1 -52�g/EASI75-16�g=60�g�����v�C

�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K
�@�BDupilumab+TCS 52�g维���v
1.IGA0,1

QW//Q2W//��Ӳ�--%

16�g39.2//38.7//14.2
52�g40.0//36.0//12.5---A

2.EASI75(%)

QW//Q2W//��Ӳ�--%

16�g63.9//68.9//23.2
52�g64.1//65.2//21.6 �K�KB

52�g/16�g=95%, �����h5%�A维���v95%.

3.IGA0,1 �����v ,Q2W, A/B=36/68.9=52%

�G�BLebrikizumab 52 �g维���v�C
��16�g,�FEASI75 OR IGA0,1�������̬���¦�A�t��18-52�g�v���C
1�PADvocate 1(�b��16�g��59%�FEASI75�^

Lebrikizumab 250 mg
Q4W//Q2W

IGA (0,1) 74 %//76 %
EASI�@75 79%//79%

2�PADvocate2�]�b��16�g51%�FEASI75�^
Q4W//Q2W
IGA (0,1) 81 %//65 %
EASI-75 85 %//77 %

�T�BTralokinumab 52�g�����v
��16�g,�FEASI75 OR IGA0,1��������,�t�i��18~52�g Q2W/Q4W/Q2W�w����

(1)ECZTRA 1
Q2W//Q4W/Q2W�w����
A.IGA0,1 51%//39%//47%
B.EASI-75 60%//49%//33%

(2)ECZTRA 2
Q2W//Q4W/Q2W�w����
A.IGA0,1 59%//45%//25%
B.EASI-75 56%//51%//21%

ir.aslanpharma.com/static-files/712eae9b-859b-45f2-81d2-08a2de03bc86

������ܯǴ��F�J�ꥻ�����W�����q��
2022 �~ 9 �� 14 ��AASLAN Pharmaceuticals Limited�]�����q���^�V�Ǵ��F�J�Ѳ������]���Ǵ��F�J���^�W����泡����F�N��N�����q�Ѫ�����s�U�Ѳ��]��ADS���^�����W�����ӽФ��q�q�Ǵ��F�J���y������Ǵ��F�J�ꥻ�����C 2022 �~ 9 �� 27 ��A���q����Ǵ��F�J�q���A�� ADS �����W���ӽФw����C�����N�� 2022 �~ 9 �� 29 ��}�~�ɥͮġC���q�N�~��H��ASLN�����N�X�i�����C
�Ǵ��F�J�ꥻ�����O�@�ӳs���������A��B�@�覡�P�Ǵ��F�J���y�����ۦP�C�Ҧ��b�Ǵ��F�J�ꥻ�����W�������q�����������Y�ǰ]�ȭn�D�ÿ��u�Ǵ��F�J�����q�v�z�зǡC���q�{���A���ŦX�b�Ǵ��F�J�ꥻ�����~��W�����Ҧ��A�μзǡA���ŦX 1.00 ��������л���n�D�A���p���q���e�b 2022 �~ 4 �� 1 �鴣�檺���� 6-K ���ť������ˡC���q�ŦX�����B�~�� 180 �ѡ]�Ϊ��� 2023 �~ 3 �� 27 ��^�H���s���u�̧C��л���A�o�n�D���q ADS �����L��л��楲���b�ܤֳs��Q�Ӥu�@�餺�ܤ֬��C�� 1.00 ����.�p�G���q�L�k�b�B�~�� 180 �ѦX�W������_�X�W�A���q����b���n�ɶi��ϦV�Ѳ������ ADS ��v�ܧ�C
������ 6-K ���]�t���H���S���q�L�ޥΨ֤J���q������� F-3 �����U�n���]��� 333-234405�^�B���� F-3 �����U�n���]��� 333-252575�^�B���UF-3 �����n���]���s�� 333-254768�^�BS-8 ����n�O�n���]���s�� 333-252118�^�M S-8 ����n�O�n���]���s�� 333-263843�^

Notice of Transfer of Listing to The Nasdaq Capital Market
On September 14, 2022, ASLAN Pharmaceuticals Limited (the ��Company��) submitted to the Listing Qualifications Department of the Nasdaq Stock Market (��Nasdaq��) an application to transfer the listing of its American Depositary Shares (��ADSs��) representing ordinary shares of the Company from The Nasdaq Global Market to The Nasdaq Capital Market. On September 27, 2022, the Company received notice from Nasdaq that its application to transfer listing of its ADSs had been approved. The transfer will be effective at the opening of business on September 29, 2022. The Company will continue to trade under the symbol ��ASLN.��
The Nasdaq Capital Market is a continuous trading market that operates in the same manner as The Nasdaq Global Market. All companies listed on The Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq��s corporate governance standards. The Company believes it is in compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, but for the $1.00 bid price requirement, as previously announced on Form 6-K filed by the Company on April 1, 2022. The Company is eligible for an additional 180-day period (or until March 27, 2023) to regain compliance with the minimum bid price, which requires that the closing bid price of the Company��s ADSs must be at least $1.00 per share for a minimum of ten consecutive business days. In the event that the Company is not able to regain compliance during the additional 180-day compliance period, the Company intends to effect a reverse stock split or ADS ratio change, if necessary.
The information contained in this Form 6-K is hereby incorporated by reference into the Company��s Registration Statement on Form F-3 (File No. 333- 234405), Registration Statement on Form F-3 (File No. 333-252575), Registration Statement on Form F-3 (File No. 333-254768), Registration Statement on Form S-8 (File No. 333-252118) and Registration Statement on Form S-8 (File No. 333-263843).

ASLAN Pharmaceuticals �b�� 51 ���ڬw�ֽ��f��s�Ƿ|�~�|�W�H��i�̷s���q�l�����i�� Eblasakimab ���s�ƾ�

�ȴ����ķ~�������q
2022 �~ 9 �� 28 ��A�P���T�A�ߤW 7:00
�b���夤�G

Shawn Kwatra �դh�M Madan Kwatra �դh�X�@���Ĥ@��ƾ���ܡA�S���ʥ֪� (AD) �w�ֽ̥��˥����Τj�ӭM�M�ݻĩʲɲӭM�� IL-13R�\1 ���F�W�[�A�W�j�F IL-13R�\1 ���֤ߧ@��

Eblasakimab ��ۭ��C�F�Ѥ��P�� IL-4 �M IL-13 ��o�~�|�ް_�����g����o�ӷP�ʡA�åB�T�w�F IL-13R�\1 �H���b���� AD �H�~�����g�����ĩʩM�ӷP�ʤ����s���@��

�[�Q�֥��Ȧ{�������J�M�s�[�Y�A2022 �~ 9 �� 28 �� (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) �O�@�a�{�ɶ��q�B�H�K�̾Ǭ����I���ͪ��s�Ĥ��q�A�}�o�зs���k�H���ܱw�̪��ͬ��A���ѫť��F�b�� 51 ���ڬw�ֽ��f�Ǭ�s�Ƿ| (ESDR) �|ij�W���зs����Ʃʨ̥��Գ߳�ܼƾڡC 2022 �~ 9 �� 28 ��� 10 �� 1 ��b�������i���S���|�檺�j�|�����A��T�����H�q�l�������Φ��e�{�C

���b ESDR �W�i�ܪ��s��Ƽƾڬ� AD �� IL-13R�\1 ���ɪ��ӭM�]�l�H���Ǿɴ��ѤF�s�o�M�t���ƪ�����ѡC�ڭ̻P Shawn Kwatra �դh�M Madan Kwatra �դh�X�@����B�ƾ���ܡAIL-13R�\1 �b�Τj�ӭM�M�ݻĩʲɲӭM�������F�����A�o�O AD ���g�������X�ʦ]���A�b�o���ֽ����f�ܳ���A�[�j�F IL-13R�\1 �b���� AD �f�z�ǡA��ASLAN Pharmaceuticals ��Ƭ�ǭt�d�H Ferda Cevikbas �դh���C �����~�A��]���F���ܤƪ��� 1 ���M 2 �����餧���s�b�򥻪��H���Ǿɮt���A�w��o�Ǩ��骺�Ī��i��㦳���P���U������A�q�ӾɭP���P���{�ɵ��G�C�Ӧۯ��g����s���ƾ��ҹ�F�ڭ̤��e���o�{�A�Y IL-13R�\1 �H���Ǿɹ�󯫸g���q�L�S�w��o�������o�~�|���ӷP�ʫܭ��n�A�í������� IL-13R�\1 �H���Ǿɥi��b���� AD �H�~�����g�����ĩʩM�ӷP�ʤ譱�o������@�ΡC�o�Ǽƾڤ���F IL-13R�\1 �@�� AD �v�I�����n�ʡA�� eblasakimab � AD �w�̪����g�M��o���ѤF�@�ؼ�b���t���Ƥ�k�C��

2022 ESDR �q�l�����Ա�

���� 1

IL-13R�\1�H���b�S���ʥ֪������Ŷ��w��M�\��@��
�]�K�n�s���GLB060�^

�Q��

AD �O�@�غC�ʪ��g�ʥֽ��f�A�񦳩��㪺��o�]��o�^1�C�o�OAD�w�̳��i�����c�����g���C IL-4/IL-13 ����t�άO�g�{�����Ҫ� AD �v���v�I�A�� 1 ���]IL-14R�\1 �M���@ �^ ��^�M 2 ���]�� IL-4R�\1 �M IL-13R�\1 �զ��^����զ�2 .�����i�ܤF�� AD �w�ֽ̥��� IL-13R�\1 ���F�Ҧ������R���G�A�ûP���d��Ӳնi��F����A�Ӭ�s���b�q�L�K�̲�´�ƾ� (IHC) �M�Ŷ��w���n�a�F�� IL-13R�\1 �b AD �����@�ΨϥΤ������վǨӴy�z 1 ���M 2 �����骺�\��C

���G

�ƾ���ܡA�P�ǰt�����d��Ӭۤ�A�l�� (L) (P<0.001) �M�D�l�� (NL) (P=0.45) AD �ֽ��� IL-13R�\1 ���F��ۼW�[�C���~�A�P�ǰt����Ӭۤ�AL�]���O�� P = 0.034 �M P = 0.024�^�M NL�]���O�� P = 0.031 �M P = 0.046�^AD �ֽ����Τj�ӭM�M�ݻĩʲɲӭM�W�� IL-13R�\1 ���F��ۼW�[�C�Χܱ`�� �^ �������� 1 ������ɭP MMP9 �����F�W�[�]P<0.001�^�A�o�O�@�ؽ���酶�A�b AD �w�̤��ɰ��A�åi��[�@���g�P�i��´���~ 3�B4�C eblasakimab �� 2 �����骺����ɤF��]�A�G�����ɪ� 2 ���s���M�ӭM�]�l���ͩһݪ� XBP1�]P<0.001�^�M CXCL8�]P=0.046�^�b������]������A������P AD �Y���{�׬���6�C

���� 2

���� 2

�̥��Ԩ��ܹv�V�ղӭM���� 13 ���� �\ 1 (IL-13R�\1) �}��s����o�~�|�M�۵o���g������
�]�K�n�s���GLB061�^

�Q��

IL-4 �M IL-13 ����o�~�|�M���g�����ĩʦ����㪺�v�T�A�i�H�q�L�v�V IL-13R�\17,8 �ӧ���C Eblasakimab �H���˩M�O�P�H 2 ������Ȱ� IL-13R�\1 ���X�A���� IL-4 �M IL-13 �q�L�b�@�t�C�K�̩M�D�K�̲ӭM�]�]�A�Pı���g���^�W���F�� 2 ������o�X�H�� 7,9�C�Pı���g�����P�ӧΦ��F�h������Pı��ê���ӭM�M���l��¦�A�Ҧp�C����o�B���g���ʪ��g�M�k�h�\���ê���Φ��C�����i�ܤF�@����s�����G�A�Ӭ�s���b�T�w�H���I�گ��g�` (hDRG) ���g���b�U�ر���U����o�커�ɪ���o�H�������g�������C�b�t���w�E肽�M�e�C���������g�� (IS) ���ɪ� hDRG ���g�����AIL-4 �M IL-13 ��۵o���g������ (SA) ���v�T�A�b�ϥΩM���ϥΨ�blasakimab �@���Pı���g���W�ӤƼҫ������p�U�i��F���q�C

���G

�����������Ѫ��ƾ��ҹ�F eblasakimab ����� IL-4 �M IL-13 ��H�����g���ް_�����g���P�Ӫ����e���G�C���~�AIL-13 �� hDRG ���g����P�ǤW������肽 1-20 (PAMP20) �ӷP�A�ҩ��F�o�S���� MRGPRX2 ����b�H���Pı���g�������F�õo���@�ΡA���� 2 ���ӭM�]�l�b�h�زӭM�]�l�����W�j�@�λP��o�������e�f�C�b���g����U�AIL-4 �b hDRG ���g�������ɦ۵o���� (SA)�A�� eblasakimab ��ۭ��C�F�۵o���ʡC�o�i��O���g����U���g���ӷP�ʧ��ܪ������¦�C�o�Ǽƾڪ����AIL-13 �M IL-4 �i��b�v�T���g�����ʤ��o�����P���@�ΡA�Ө̥��Ԧ��ܳQ�ҩ��i�H���_�o��زӭM�]�l���@�ΡC

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting

finance.yahoo.com/news/aslan-pharmaceuticals-presents-data-eblasakimab-110000948.html

�X�Q�Ԫ��v�T
�ڬw����g�٤����[
���~�V�ѥi�������F
�ڬw�ϥi�ण�}�Hwww.clinicaltrials.gov/ct2/show/NCT05158023
8��30��
004 2b�w�}65�Ӥ���.
欧�{�ϥi�ण�}�H�@.ASLAN004 2b 16�g�����
ASLAN004 VS��Ӳ�//�t��(������Ӳ�)

IGA 0,1= 57% VS 15%//�t��42%(57%-15%=42%)
EASI75= 73% VS 24%//�t��49%(73%-24%=49%)

�G.Tralokinumab �w��,�h�~12�� ��FDA ,��-��AD�����ĵ�(DUPILUMAB �᪺�@�ɲĤG��,DUPILUMAB).
MOA:�@�ΦbIL13 �t��A,D���ۤW,�ϱoIL13 �T���L�k�Q�ǻ�.��IL4 �T���i���`�ǻ�.

(�@).ECZTRA 1
1.IGA0,1

Q2W//Q4W VS ��Ӳ� //������Ӳի�
16�g 15.8%//-- VS 7.1% // 8.7%
52�g 8.1%//6.2%

2.EASI75

16�g 25%//-- VS 12.7%//12.3%
52�g 15%//12.3%

(�G).ECZTRA 2

1.IGA 0,1
Q2W//Q4W VS ��Ӳ� //������Ӳի�
16�g 22.2%//--VS 10.9% //11.3%
52�g 13.1%//10.0%

2.EASI75
16�g 32.2%//--VS 11.4%//20.8%
52�g 18.0%//16.4%

pubmed.ncbi.nlm.nih.gov/33000465/

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

1.At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1:
15�P8% vs. 7�P1% in ECZTRA 1 [difference 8�P6%, 95% confidence interval (CI) 4�P1-13�P1; P = 0�P002] and 22�P2% vs. 10�P9% in ECZTRA 2 (11�P1%, 95% CI 5�P8-16�P4; P < 0�P001)

and EASI 75: 25�P0% vs. 12�P7% (12�P1%, 95% CI 6�P5-17�P7; P < 0�P001)
and 33�P2% vs. 11�P4% (21�P6%, 95% CI 15�P8-27�P3; P < 0�P001).

www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/

(�T)Tralokinumab 52�g�����v
��16�g,�FEASI75 OR IGA0,1��������,�t�i��18~52�g Q2W/Q4W/Q2W�w����

(1)ECZTRA 1
Q2W//Q4W/Q2W�w����
A.IGA0,1 51%//39%//47%
B.EASI75 60%//49%//33%

(2)ECZTRA 2
Q2W//Q4W/Q2W�w����
A.IGA0,1 59%//45%//25%
B.EASI75 56%//51%//21%

�b�ⶵ���� 52 �g�B�H���B�����B�w������Ӫ� III ������ ECZTRA 1 �M ECZTRA 2 ���A���צܭ��� AD �����H�Q�H�� (3:1) �����C 2 �g 300 mg �� tralokinumab �֤U�`�g�C Q2W�^�Φw�����C
�D�n���I�O�� 16 �g�ɬ�s�̪�������� (IGA) ������ 0 �� 1�A�� 16 �g����l���n�M�Y���ʫ��� (EASI 75) �ﵽ≥ 75%�C

IGA ������ 0 �� 1 �M/�� EASI 75 ���w�� �b�� 16 �g�ϥ� tralokinumab ���w�̳Q���s�H�����t�� tralokinumab Q2W �ΨC 4 �g�@���Φw�����A���� 36 �g�C

�o�Ǹ���w�b ClinicalTrials.gov ���U�GNCT03131648 �M NCT03160885�C

In two 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator��s Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885.

�T.ASLAN004 2b ����� VS Tralokiumab 3��(16�g) ������Ӳ�

1.ASLAN004 2b �����
IGA 0,1= 57% VS 15%//�t��42%----A
EASI75= 73% VS 24%//�t��49%----B

vs

2.Tralokiumab 3��(16�g)---������Ӳ�

IGA 0,1= �t��8.7%~11.3%,����10%---C

EASI75= �t��12.3%~20.8%,����16.6%---D

3.16�gPK
IGA 0,1 A/C=42%/10%=420%
EASI75 B/D=49%/16.6%=295%

�|:����ASLAN004 �����,�T���D�n���� IGA0,1 //EASI75 ��w�b��/�ڤW����Tralokiumab(�@�ɲĤG�W���w��)
�����X320%//195%.

ASLAN004 AD�ĵ� �䤣��z�Ѯ�����.
�����Ȧ��h���nPK�����O

Dupilumab �T�� Q2W
IGA 0,1= 38% VS 10%//�t��28%----SOLO1
=36% VS 8% //�t��28%----SOLO2
EASI75= 51% VS 15%//�t��36%----SOLO1
= 44% VS 12%//�t��32%----SOLO2

Leb. PK Dupilumab�A(�Ҧ��T���A�Υ[TCS�A��16/52�g)�A�������组�v�T

Leb. 40% �u��Dup.
��
Leb. 39% �H��Dup.

Lebrikizumab �QTCS��16�g �T���A�������组
@%
IGA. 41-22=19
EASI75 70-42=28

�G�BDupilumab +TCS 16�g�A�������组
@%
IGA. 38.7-14.2=24.5
EASI75 68.9-23.2=45.7

�T�APK

Leb./Dup.
@%
IGA. 19/24.5=78
EASI75 28/45.7=61

结�� �[TCS��ALeb. �H�� Dup.

�bIGA.�H22%,
�bEASI75 �H39%.

Leb.�QTCS �MLeb.AD2 �T��/16�g�q�İ�¦���۪�C

Leb. AD2 16�g�C
IGA. 33-11=22
EAS75 51-18=33

Dupilumab+TCS vs Dupilumab (SOLO1/2 Q2W),

EASI75(%) pk�A�K�K�T���{��

1.Dep.+TCS
QW//Q2W//��Ӳ�--%

16�g63.9//68.9//23.2
52�g64.1//65.2//21.6

52�g/16�g=95%, �����h5%

2.Dup. SOLO 1/2 Q2W--%

16�g 51/44,����47.5

3.pk

68.9/47.5=145...16�g

Dupilumab�Q TCS�A�b��16�g�۹�󥼥[TCS,
EASI75,�W�[45%�����ġC

�B52�g�u��5%.

�G�BLebrikizumab �QTCS �T���{��x16�g�v���A
2022/4/22
���G�C���G

1.Leb.+TCS vs ���组

1.IGA0,1 41 vs 22
2.EASI75 70 vs 42

3.Leb.+TCS pK Lebrikizumab 1EASI76,
16 �g
AD1/AD2 59/51,����55

70/55=127%,�W�[27%
TCS �W�[EADI75 27%����
...........................
News Release
Lilly��s Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
April 11, 2022

Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including
skin and itch, in pivotal combination trial that met all primary and key secondary endpoints

INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS.

Today��s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either alone or combined with topicals, said Eric Simpson, M.D., M.C.R., Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland, and principal investigator of ADhere. Lebrikizumab specifically targets the IL-13 pathway, which plays the central role in this chronic inflammatory disease. These results strengthen our understanding of lebrikizumab in atopic dermatitis and help establish it as a possible new treatment option.

Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R�\1/IL-4R�\ (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.1-5 IL-13 plays the central role in Type 2 inflammation in AD.6,7 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.8

Among patients taking lebrikizumab plus TCS, 41 percent achieved clear or almost clear skin (IGA) at 16 weeks compared to 22 percent of patients taking placebo plus TCS. At 16 weeks, 70 percent of patients taking lebrikizumab plus TCS achieved an EASI-75 response compared to 42 percent taking placebo plus TCS. Differences between patients receiving lebrikizumab in combination with TCS and placebo with TCS were observed as early as four weeks for EASI-75.

�j������Lebrikizumab �T��52�g���ƾڰ�¦�T���̩w�q �O16�g�ɹF EASI75 ,�DEASI50(�@��AD �v���� Responders���w�q��EASI50)

* Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (clear or almost clear) with a 2-point improvement and without rescue medication use at Week 16.

* �T���̩w�q����l���n�M�Y���{�׫��Ʊq��u (EASI-75) ��� 75% �� IGA 0 �� 1�]���M�����Ρ��X�G�M�����^�A�ﵽ 2 ���B���i��ϴ����H �� 16 �g���Ī��ϥα��p�C

Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly��s Phase 3 Monotherapy Atopic Dermatitis Trials
September 8, 2022

finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html

�@.Lebrikizumab 52�g���v���ĪG---�̰�u�Ĥ@�g���p��¦--------�j�ץ��p�U:

1�AAD1.
52�gQ4W//Q2W

IGA �G59%(EASI75)x74%//76%
=47%//45%

Vs 16�g���� 43%�A�g18��52�g�v������p����IGA 4%//2%

EASI75: 59%(EASI75)x79%//79%%
=47%

Vs 16�g���� 59%�A�g18��52�g�v������pEASI75,�˰h12%�C

2.AD2

IGA �G51%(EASI75)x81%//65%
=41%//33%

Vs 16�g���� 33%�g18��52�g�v������p����IGA 8%//0%

EASI75: 51%�]EASI75)x85%//77%
=43%//39%

Vs 16�g���� 51%�g18��52�g�v������p �˰hEASI75 8%//12%

���סG�q16�g������52�g�M����IGA �ĪG ��������3.5%�A
����EASI75 �����U��11%�C

�@�@�@�@�@�@�@�@�@�@

Lebrikizumab Week 52 Results

1�PADvocate 1(�b��16�g��59%�FEASI75�^

Lebrikizumab 250 mg
Q4W//Q2W

IGA (0,1) 74 %//76 %
EASI�@75 79%//79%
Pruritis (Itch) NRS 80 %//81 %

2�PADvocate2�]�b��16�g51%�FEASI75�^
Q4W//Q2W
IGA (0,1) 81 %//65 %
EASI-75 85 %//77 %

Pruritis (Itch) NRS 88 %//90 %

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)